{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":57,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":57,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"458495b2c95b","filters":{"venue":"Targeted Oncology"}},"results":[{"id":"W2742486699","doi":"10.1007/s11523-017-0518-1","title":"Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars","year":2017,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":171,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Intensive care medicine; Internal medicine; Cancer; Chemotherapy","authors":[{"name":"Lee S. Rosen","is_ca":false},{"name":"Ira Jacobs","is_ca":false},{"name":"Ronald L. Burkes","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06030926735329518,"gpt":0.4066597918623675,"spread":0.3463505245090723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002972848,0.000486821,0.0005958052,0.001201308,0.0003636686,0.002058045,0.000522128,0.001901286,0.001858674],"category_scores_gemma":[0.003838211,0.0001871307,0.0004092244,0.001276092,0.001349157,0.002491899,0.000913287,0.0029515,0.000997139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001348124,"about_ca_system_score_gemma":0.001327268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001061649,"about_ca_topic_score_gemma":0.001558487,"domain_scores_codex":[0.9986959,0.0004586864,0.0001175096,0.0001492392,0.0004917942,0.00008693144],"domain_scores_gemma":[0.9978831,0.001079781,0.0003320249,0.00005039139,0.0004339375,0.0002207352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001621425,0.00009284972,0.000525698,0.003374015,0.00003717651,0.0002242289,0.0001912677,0.000543733,0.003462695,0.0262158,0.03014983,0.9350206],"study_design_scores_gemma":[0.00002646979,0.0004251426,0.000887349,0.001709703,0.00004328117,0.001545516,0.0001202194,0.0003936418,0.001418047,0.01064199,0.9827597,0.00002902323],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007560202,0.9880927,0.0007102545,0.007556248,0.000622111,0.000005524435,0.00001120875,0.00001480001,0.002231028],"genre_scores_gemma":[0.008657684,0.984323,0.0009626306,0.002557126,0.00209923,0.00001354362,0.00002987159,0.000009156754,0.001347923],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002972848,"threshold_uncertainty_score":0.0157221,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","authors":[{"name":"Zev A. Wainberg","is_ca":false},{"name":"María Alsina","is_ca":false},{"name":"Heloisa P. Soares","is_ca":false},{"name":"Irene Braña","is_ca":true},{"name":"Carolyn D. Britten","is_ca":false},{"name":"Gianluca Del Conte","is_ca":false},{"name":"Patrick I. Ezeh","is_ca":false},{"name":"Brett E. Houk","is_ca":false},{"name":"Kenneth A. Kern","is_ca":false},{"name":"Stephen Leong","is_ca":false},{"name":"Kristen J. Pierce","is_ca":false},{"name":"Lillian L. Siu","is_ca":true},{"name":"Jennifer Vermette","is_ca":false},{"name":"Josep Tabernero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03309205630219511,"gpt":0.3685072594238245,"spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00349104,0.002378311,0.002051574,0.00104555,0.000532765,0.001143409,0.00173049,0.001456052,0.004394241],"category_scores_gemma":[0.001221677,0.001134225,0.002014865,0.0006373993,0.001282831,0.001493744,0.0007104797,0.004390095,0.001071451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001518053,"about_ca_system_score_gemma":0.002447292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008640112,"about_ca_topic_score_gemma":0.002415756,"domain_scores_codex":[0.9990588,0.0004291232,0.00005114848,0.0001775427,0.0001077291,0.0001757218],"domain_scores_gemma":[0.9987588,0.0001485979,0.0002741838,0.0001519581,0.00006735188,0.0005990266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7101741,0.1596669,0.00332307,0.0007116578,0.001347211,0.0001775106,0.0002480684,0.004214264,0.05712755,0.0003345527,0.002563281,0.06011192],"study_design_scores_gemma":[0.5399032,0.4497955,0.003917787,0.00001717689,0.0003311874,0.0001388651,0.00002344779,0.0009776079,0.003290399,0.000190998,0.001381631,0.0000321085],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905084,0.0009690679,0.001212432,0.0003741493,0.0001285098,0.004281206,0.0008603957,0.0001280165,0.001537799],"genre_scores_gemma":[0.9800028,0.001245646,0.004988215,0.0008786224,0.0002240841,0.005907453,0.002699518,0.00004966136,0.004004062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004394241,"threshold_uncertainty_score":0.0184626,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2914232272","doi":"10.1007/s11523-018-00617-1","title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Nausea; Proteinuria; Adverse effect; Peripheral edema; Internal medicine; Vomiting; Dosing; Pharmacodynamics; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Kidney","authors":[{"name":"Maja J.A. de Jonge","is_ca":false},{"name":"Neeltje Steeghs","is_ca":false},{"name":"Martijn P. Lolkema","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Hal W. Hirte","is_ca":true},{"name":"Diane A.J. van der Biessen","is_ca":false},{"name":"Albiruni R. Abdul Razak","is_ca":true},{"name":"Filip De Vos","is_ca":false},{"name":"Remy B. Verheijen","is_ca":false},{"name":"David Schnell","is_ca":false},{"name":"Linda Pronk","is_ca":false},{"name":"Monique Jansen","is_ca":false},{"name":"Lillian L. Siu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02749436018870834,"gpt":0.3522023992081704,"spread":0.3247080390194621,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009912362,0.001232024,0.001301852,0.0003808904,0.0003301471,0.0005995421,0.0006727743,0.0006147077,0.002187142],"category_scores_gemma":[0.0004623796,0.0003825748,0.000572112,0.0004069415,0.0004505902,0.0004489868,0.0003086204,0.001670762,0.0005933195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006274831,"about_ca_system_score_gemma":0.001038336,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000847122,"about_ca_topic_score_gemma":0.002487573,"domain_scores_codex":[0.999759,0.0001008116,0.0000131838,0.00003849429,0.00003150708,0.00005692614],"domain_scores_gemma":[0.999688,0.00005019321,0.00006437417,0.00002222566,0.00002219971,0.0001529953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2909061,0.09638848,0.03611322,0.001684196,0.001981185,0.001011877,0.001044449,0.008545019,0.2206175,0.0007280468,0.01066922,0.3303108],"study_design_scores_gemma":[0.2644172,0.6510839,0.05692464,0.00007061425,0.0007527281,0.001309848,0.0001037217,0.004553745,0.01363909,0.0003219873,0.006777914,0.00004468645],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925195,0.002790001,0.000656267,0.0002268163,0.00003460196,0.001652785,0.000552645,0.000109051,0.001458383],"genre_scores_gemma":[0.9931854,0.001376001,0.001667707,0.0004427257,0.00005098933,0.0009865991,0.001287309,0.00001615937,0.0009869247],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002187142,"threshold_uncertainty_score":0.007316709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2201788027","doi":"10.1007/s11523-015-0396-3","title":"Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Prostatic adenocarcinoma; Pathology; Lymphocyte; Castration; Prostate cancer; Oncology; Internal medicine; Cancer","authors":[{"name":"Francesco Massari","is_ca":false},{"name":"Chiara Ciccarese","is_ca":false},{"name":"Anna Caliò","is_ca":false},{"name":"Enrico Munari","is_ca":false},{"name":"Luca Cima","is_ca":false},{"name":"Antonio Benito Porcaro","is_ca":false},{"name":"Giovanni Novella","is_ca":false},{"name":"Walter Artibani","is_ca":false},{"name":"Teodoro Sava","is_ca":false},{"name":"Albino Eccher","is_ca":false},{"name":"Claudio Ghimenton","is_ca":false},{"name":"Francesco Bertoldo","is_ca":false},{"name":"Aldo Scarpa","is_ca":false},{"name":"Nicola Sperandio","is_ca":false},{"name":"Camillo Porta","is_ca":false},{"name":"Vincenzo Bronte","is_ca":false},{"name":"Marco Chilosi","is_ca":false},{"name":"Giuseppe Bogina","is_ca":false},{"name":"Giuseppe Zamboni","is_ca":false},{"name":"Giampaolo Tortora","is_ca":false},{"name":"Hemamali Samaratunga","is_ca":false},{"name":"Guido Martignoni","is_ca":false},{"name":"Matteo Brunelli","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03854617420081482,"gpt":0.3205983842461482,"spread":0.2820522100453334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004754415,0.0001795674,0.0002831857,0.000700828,0.0002185584,0.0004486046,0.0001727863,0.0002360282,0.001375369],"category_scores_gemma":[0.0006107381,0.0001260189,0.0002567182,0.0003447411,0.0002680406,0.0002392727,0.0002699629,0.0003651163,0.0002276177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001875955,"about_ca_system_score_gemma":0.0001421356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008201516,"about_ca_topic_score_gemma":0.0009496273,"domain_scores_codex":[0.9997597,0.00005998611,0.00001613396,0.0000375751,0.00007105398,0.00005562812],"domain_scores_gemma":[0.9995154,0.0002071773,0.00007248481,0.00004957547,0.00006398129,0.00009139664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01062118,0.0004786887,0.156001,0.0001968101,0.000156065,0.0004966172,0.0003879078,0.001093074,0.8154245,0.0001707723,0.000158221,0.01481508],"study_design_scores_gemma":[0.00005742105,0.00586287,0.878004,0.000008952692,0.0001707695,0.001888778,0.000778724,0.001542294,0.1100479,0.00009299482,0.001529875,0.00001552886],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988674,0.0002522597,0.0001522636,0.000006579176,0.000002053649,0.00001064807,0.0001987849,0.000005029989,0.0005050763],"genre_scores_gemma":[0.9988835,0.0001259337,0.0001459382,0.00001199485,0.000005263782,0.0000118387,0.0003665978,0.000003438965,0.0004455064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001375369,"threshold_uncertainty_score":0.004601121,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1999755104","doi":"10.1007/s11523-014-0308-y","title":"Transforming growth factor-beta and its implication in the malignancy of gliomas","year":2014,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Glioma; Medicine; Cancer research; Malignancy; Transforming growth factor beta; Angiogenesis; Cytokine; Growth factor; Transforming growth factor; Pathology; Hepatocyte growth factor; Immunology; Internal medicine; Receptor","authors":[{"name":"Laurent-Olivier Roy","is_ca":true},{"name":"Marie-Belle Poirier","is_ca":true},{"name":"David Fortin","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02932850146755989,"gpt":0.3367804522802084,"spread":0.3074519508126485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004124887,0.0006124746,0.0009662082,0.001357449,0.0001681755,0.000884017,0.000619657,0.0008186786,0.001876873],"category_scores_gemma":[0.0005051849,0.0001999118,0.0002909859,0.001496629,0.0004065345,0.0007316557,0.0004852277,0.001545466,0.001096924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005658878,"about_ca_system_score_gemma":0.0009958622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001049932,"about_ca_topic_score_gemma":0.002073409,"domain_scores_codex":[0.9998958,0.00001327031,0.00001388858,0.00001630519,0.00004660193,0.00001406704],"domain_scores_gemma":[0.9998171,0.0000756811,0.00003456698,0.000005111517,0.00004575505,0.00002183704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001059192,0.00004727529,0.0002079863,0.008929552,0.00007693232,0.0003145583,0.00003800535,0.0004088338,0.002558689,0.003880707,0.02701966,0.9564118],"study_design_scores_gemma":[0.0000265405,0.00006343499,0.0008766108,0.001760724,0.0001453439,0.001701194,0.00004757658,0.0001165789,0.0009788335,0.00239555,0.9918678,0.00001987403],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001001616,0.9990308,0.00009882583,0.0002182845,0.0001116531,0.000001710339,0.00001152476,0.000003914116,0.0004231288],"genre_scores_gemma":[0.0007552426,0.9985375,0.0001175382,0.0001200072,0.0001473186,0.000002560142,0.00001739519,7.631411e-7,0.0003015376],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001876873,"threshold_uncertainty_score":0.006278753,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1627803359","doi":"10.1007/s11523-015-0386-5","title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer research; Sulforaphane; Protein kinase B; PI3K/AKT/mTOR pathway; Clonogenic assay; Apoptosis; Bladder cancer; Epithelial–mesenchymal transition; Survivin; Pharmacology; Cancer; Internal medicine; Chemistry; Metastasis; Biochemistry","authors":[{"name":"Syed S. Islam","is_ca":true},{"name":"Reza Bayat Mokhtari","is_ca":true},{"name":"Paniz Akbari","is_ca":true},{"name":"Jiřı́ Hatina","is_ca":false},{"name":"Herman Yeger","is_ca":true},{"name":"Walid A. Farhat","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01358908671145698,"gpt":0.2522022828085155,"spread":0.2386131960970586,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001026184,0.0002747791,0.0002788701,0.000171151,0.0001358674,0.0001786473,0.0001943643,0.0001470434,0.0007723453],"category_scores_gemma":[0.0000615872,0.00008158372,0.0001792657,0.0001610351,0.000196799,0.0001672716,0.0001480169,0.0003725883,0.00008161142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002384564,"about_ca_system_score_gemma":0.0004836489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009741575,"about_ca_topic_score_gemma":0.003363299,"domain_scores_codex":[0.9999326,0.000009051362,0.000004180881,0.00001295552,0.00001680897,0.00002432813],"domain_scores_gemma":[0.9999728,0.000004186072,0.00000803957,0.000003492368,0.000002496552,0.000009044271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0008457323,0.0001557515,0.0004120797,0.00006316344,0.00001710749,0.00005494459,0.00001655266,0.000390165,0.9846821,0.0002880788,0.000155837,0.0129185],"study_design_scores_gemma":[0.0002190065,0.003365615,0.003741577,0.000007975355,0.00008605913,0.0003536369,0.00003362673,0.002466138,0.9852372,0.0001013202,0.004377931,0.000009918072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926058,0.001967074,0.003046877,0.0001733183,0.00004211093,0.00005531056,0.0001517784,0.00007562429,0.001882081],"genre_scores_gemma":[0.9970405,0.000710911,0.001401566,0.00002310171,0.000009445707,0.00002433037,0.00006794582,0.000003794911,0.0007184518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009741575,"threshold_uncertainty_score":0.002583802,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560844514","doi":"10.1007/s11523-016-0462-5","title":"Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Sunitinib; Placebo; Quality of life (healthcare); Neuroendocrine tumors; Internal medicine; Adverse effect; Oncology; Cancer; Pathology; Alternative medicine","authors":[{"name":"Aaron I. Vinik","is_ca":false},{"name":"Andrew Bottomley","is_ca":false},{"name":"Beata Korytowsky","is_ca":false},{"name":"Yung‐Jue Bang","is_ca":false},{"name":"Jean‐Luc Raoul","is_ca":false},{"name":"Juan W. Valle","is_ca":false},{"name":"Peter Metrakos","is_ca":true},{"name":"Dieter Hörsch","is_ca":false},{"name":"Rajiv Mundayat","is_ca":false},{"name":"Arlene Reisman","is_ca":false},{"name":"Zhixiao Wang","is_ca":false},{"name":"Richard C. Chao","is_ca":false},{"name":"Éric Raymond","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08123099894244132,"gpt":0.4184935309884916,"spread":0.3372625320460503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002585311,0.001655341,0.003179436,0.0003658831,0.0004365921,0.001022399,0.0008133705,0.001350186,0.002820146],"category_scores_gemma":[0.002282275,0.0003326595,0.004674826,0.0005307498,0.001245802,0.001296537,0.0004440425,0.00376102,0.0004349636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009912716,"about_ca_system_score_gemma":0.0007105308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005599945,"about_ca_topic_score_gemma":0.001030086,"domain_scores_codex":[0.9989035,0.0005751801,0.00009184075,0.0002123299,0.00008857038,0.0001286172],"domain_scores_gemma":[0.9982975,0.0005843675,0.0005891446,0.000120822,0.000075018,0.0003331738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9492465,0.006056722,0.003111745,0.0009018587,0.004329137,0.00003962636,0.00007317697,0.001010303,0.002379358,0.00007356265,0.000736504,0.03204152],"study_design_scores_gemma":[0.793008,0.1798735,0.01920446,0.0001084908,0.00430466,0.0001130845,0.0000844427,0.000858655,0.001201144,0.0003286244,0.0008679716,0.00004685082],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865436,0.009729459,0.0003790524,0.0005188335,0.0002135136,0.0005653996,0.0008380941,0.00005252851,0.001159478],"genre_scores_gemma":[0.9938905,0.002627882,0.0005263386,0.0004104154,0.0002282139,0.0007632578,0.0008701815,0.00001485069,0.0006683924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003179436,"threshold_uncertainty_score":0.01367259,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967370517","doi":"10.1007/s11523-014-0356-3","title":"Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Neutrophilia; Lymphocytopenia; Nephrectomy; Sunitinib; Oncology; Univariate analysis; Gastroenterology; Neutrophil to lymphocyte ratio; Targeted therapy; Multivariate analysis; Cancer; Lymphocyte; Kidney","authors":[{"name":"Matteo Santoni","is_ca":false},{"name":"Sebastiano Buti","is_ca":false},{"name":"Alessandro Conti","is_ca":false},{"name":"Camillo Porta","is_ca":true},{"name":"Giuseppe Procopio","is_ca":false},{"name":"Cora N. Sternberg","is_ca":false},{"name":"Sergio Bracarda","is_ca":false},{"name":"Umberto Basso","is_ca":false},{"name":"Ugo De Giorgi","is_ca":false},{"name":"Mimma Rizzo","is_ca":false},{"name":"Lisa Derosa","is_ca":false},{"name":"Cinzia Ortega","is_ca":false},{"name":"Francesco Massari","is_ca":false},{"name":"Michèle Milella","is_ca":false},{"name":"Melissa Bersanelli","is_ca":false},{"name":"Linda Cerbone","is_ca":false},{"name":"Giovanni Muzzonigro","is_ca":false},{"name":"Luciano Burattini","is_ca":false},{"name":"Rodolfo Montironi","is_ca":false},{"name":"Daniele Santini","is_ca":false},{"name":"Stefano Cascinu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01334527017469415,"gpt":0.2400423819275469,"spread":0.2266971117528528,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003151231,0.0001801783,0.0004101445,0.0004222868,0.000311819,0.0005020576,0.0002073053,0.0003219594,0.0007934429],"category_scores_gemma":[0.001297446,0.0000821856,0.0003344612,0.0006286759,0.0002476948,0.0003383555,0.0002296637,0.0004618033,0.0001043854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002859007,"about_ca_system_score_gemma":0.0003251601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006682278,"about_ca_topic_score_gemma":0.001084457,"domain_scores_codex":[0.9998388,0.00003686242,0.00002024275,0.00002743765,0.00002644631,0.00005013987],"domain_scores_gemma":[0.9991114,0.0002064944,0.0003719172,0.00003335464,0.00007808077,0.0001986862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006305893,0.0000284939,0.9951128,0.00001024277,0.00004446689,0.000164928,0.00002630399,0.00009691913,0.0007091807,0.00001944283,0.00007688674,0.00307965],"study_design_scores_gemma":[0.0000238944,0.0004341672,0.9969086,0.00000859077,0.000116927,0.0009582892,0.0001300628,0.0005297763,0.0003502367,0.00008290364,0.0004505556,0.000006091117],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983777,0.0008143156,0.00009045585,0.00007104446,0.00001432857,0.000003955749,0.0001032449,0.000003682314,0.000521242],"genre_scores_gemma":[0.9995587,0.0001232048,0.00003987026,0.00002886484,0.0000254888,0.000002930772,0.0001285514,0.000001101047,0.00009125471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007934429,"threshold_uncertainty_score":0.002654374,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037096531","doi":"10.1007/s11523-012-0252-7","title":"The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; VEGF receptors; Internal medicine; Second-line therapy; Cancer; Chemotherapy","authors":[{"name":"Mhd Yaser Al-Marrawi","is_ca":false},{"name":"Brian I. Rini","is_ca":false},{"name":"Lauren C. Harshman","is_ca":false},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"Lori Wood","is_ca":true},{"name":"Ulka N. Vaishampayan","is_ca":false},{"name":"Mary J. MacKenzie","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Neeraj Agarwal","is_ca":false},{"name":"Hulayel Alharbi","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Min-Han Tan","is_ca":false},{"name":"Sun Young Rha","is_ca":false},{"name":"Frede Donskov","is_ca":false},{"name":"Scott North","is_ca":true},{"name":"Toni K. Choueiri","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07733604392423403,"gpt":0.3777414729966405,"spread":0.3004054290724065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008194342,0.0001729379,0.0004716959,0.0004012901,0.0002749064,0.0007790988,0.0002522959,0.0004636174,0.002198781],"category_scores_gemma":[0.00345226,0.00007870582,0.0007797063,0.0005377993,0.0002613268,0.0005038336,0.0003887435,0.0009366968,0.0002673892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005746213,"about_ca_system_score_gemma":0.0005271902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001123138,"about_ca_topic_score_gemma":0.001528359,"domain_scores_codex":[0.9995285,0.0001131804,0.00004721825,0.00007738132,0.0000706616,0.0001631163],"domain_scores_gemma":[0.9972875,0.0008248062,0.0009685339,0.0001031123,0.0002141654,0.0006018865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00222115,0.00009989495,0.9887372,0.00002264052,0.0002734193,0.0002178924,0.00003477513,0.0003322097,0.000890135,0.0001190156,0.0003512884,0.00670048],"study_design_scores_gemma":[0.00004444733,0.0007997839,0.9966757,0.00001067334,0.0001643334,0.0005734884,0.00009593092,0.0006385756,0.000217113,0.000223719,0.0005458849,0.00001035493],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945861,0.001640206,0.0002441962,0.0003007712,0.00004071151,0.00001025483,0.0003598881,0.000009193456,0.002808608],"genre_scores_gemma":[0.99901,0.0001725119,0.00003289004,0.00006909802,0.00004510325,0.00000448263,0.000390324,0.000002928275,0.0002726029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002198781,"threshold_uncertainty_score":0.00735569,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4283026383","doi":"10.1007/s11523-022-00888-9","title":"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Multicenter study; Phases of clinical research; Internal medicine; Oncology; Clinical trial; Randomized controlled trial","authors":[{"name":"Tanya Trippett","is_ca":false},{"name":"Helen Toledano","is_ca":false},{"name":"Quentin Campbell Hewson","is_ca":false},{"name":"Arnauld Verschuur","is_ca":false},{"name":"Anne‐Marie Langevin","is_ca":false},{"name":"Isabelle Aerts","is_ca":false},{"name":"Lisa Howell","is_ca":false},{"name":"Soledad Gallego","is_ca":false},{"name":"Claudia Rössig","is_ca":false},{"name":"Amy Smith","is_ca":false},{"name":"Darshak Patel","is_ca":true},{"name":"Leonardo Pereira","is_ca":false},{"name":"Sravanthi Cheeti","is_ca":false},{"name":"Luna Musib","is_ca":false},{"name":"Katherine E. Hutchinson","is_ca":false},{"name":"Clare Devlin","is_ca":false},{"name":"Ronald J. Bernardi","is_ca":false},{"name":"Birgit Geoerger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008484783094617332,"gpt":0.271109531333761,"spread":0.2626247482391437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001230386,0.0008825727,0.001348476,0.0002348117,0.0002500215,0.0005309952,0.000407523,0.0004591137,0.000896653],"category_scores_gemma":[0.0005034858,0.0003090697,0.000696842,0.0003409209,0.0003341776,0.0004271804,0.0002202134,0.001609174,0.0003535744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007170174,"about_ca_system_score_gemma":0.001407789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009891071,"about_ca_topic_score_gemma":0.002809786,"domain_scores_codex":[0.999774,0.00009623088,0.00001893415,0.00003268204,0.00003092754,0.00004718338],"domain_scores_gemma":[0.9995516,0.00003828857,0.0001250222,0.00002573929,0.00003396715,0.0002253658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3652004,0.07223995,0.07875925,0.001632281,0.002825988,0.001708574,0.001051242,0.005158389,0.1396117,0.0005275343,0.01026029,0.3210243],"study_design_scores_gemma":[0.2631934,0.569565,0.1329261,0.0001220498,0.001426132,0.002845299,0.000240194,0.004021308,0.01429567,0.0001940476,0.01111322,0.00005759365],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960134,0.002168765,0.0001734304,0.0001883553,0.0000242246,0.0005120433,0.0003625898,0.00003252339,0.0005246917],"genre_scores_gemma":[0.9916163,0.003437155,0.001293587,0.0004976447,0.00009179586,0.000903154,0.001503762,0.00001576157,0.0006408363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001348476,"threshold_uncertainty_score":0.006506979,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4317209129","doi":"10.1007/s11523-022-00941-7","title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Pathology; Cancer; Cancer research; Internal medicine; Adenocarcinoma","authors":[{"name":"Sanjay Popat","is_ca":false},{"name":"Myung‐Ju Ahn","is_ca":false},{"name":"Simon Ekman","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Suresh S. Ramalingam","is_ca":false},{"name":"Thanyanan Reungwetwattana","is_ca":false},{"name":"Shankar Siva","is_ca":false},{"name":"Masahiro Tsuboi","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false},{"name":"James Chih‐Hsin Yang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0675653515167773,"gpt":0.4399859305321071,"spread":0.3724205790153298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004497533,0.0005935664,0.0013881,0.0009418129,0.0001235549,0.0008691061,0.0005768921,0.0005884882,0.004212374],"category_scores_gemma":[0.0005344896,0.0001542583,0.0006641304,0.001144995,0.0001936979,0.0006773317,0.0003933187,0.001289482,0.00102972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004335073,"about_ca_system_score_gemma":0.0007956504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001049575,"about_ca_topic_score_gemma":0.003852678,"domain_scores_codex":[0.9999028,0.00001639632,0.00001638083,0.00001804062,0.00003067931,0.00001578783],"domain_scores_gemma":[0.9998345,0.00008251108,0.00003451893,0.000003280197,0.00003176896,0.0000132963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002209716,0.00005507988,0.000130625,0.01740801,0.0002334909,0.00008406291,0.00002385674,0.0003846422,0.001164639,0.001462499,0.02006973,0.9587625],"study_design_scores_gemma":[0.000273985,0.0003928934,0.001558041,0.008861538,0.001133218,0.0008960186,0.00006158295,0.0002861814,0.0006347464,0.001929127,0.9839429,0.00002974074],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000184484,0.9988204,0.00006091056,0.0001692467,0.00009943598,0.000004893038,0.00003371913,0.000004595339,0.000622294],"genre_scores_gemma":[0.000969062,0.9981105,0.0001229399,0.000227211,0.00007233278,0.000006095106,0.00004760944,0.000001098608,0.0004431215],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004212374,"threshold_uncertainty_score":0.01409179,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2091875870","doi":"10.1007/s11523-013-0271-z","title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University; Amgen (Canada)","funders":"Amgen","keywords":"Panitumumab; KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Post-hoc analysis; Colorectal cancer; Randomized controlled trial; Cancer; Confidence interval","authors":[{"name":"Melanie Poulin-Costello","is_ca":true},{"name":"Laurent Azoulay","is_ca":true},{"name":"Eric Van Cutsem","is_ca":false},{"name":"Marc Peeters","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"Michael Wolf","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009570761703216482,"gpt":0.3150242219557259,"spread":0.3054534602525095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01891291,0.001905024,0.002791923,0.0007089525,0.0003319878,0.0009170871,0.0008317949,0.001497094,0.002660479],"category_scores_gemma":[0.01720712,0.0005388326,0.007626997,0.0005747172,0.0008539241,0.0009356955,0.0006269293,0.003055272,0.0002059913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000956827,"about_ca_system_score_gemma":0.001289907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007895398,"about_ca_topic_score_gemma":0.001726624,"domain_scores_codex":[0.9873567,0.01078256,0.0003672185,0.0006117882,0.0005051321,0.0003765325],"domain_scores_gemma":[0.9827049,0.01227205,0.002774352,0.00101807,0.0004674079,0.0007631244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9591267,0.002656171,0.002843823,0.000974414,0.01275198,0.00007475507,0.00005326717,0.001419181,0.002069346,0.0001655821,0.000758458,0.01710626],"study_design_scores_gemma":[0.6744896,0.2703497,0.02273234,0.000110503,0.02401205,0.0001668138,0.00005349458,0.003648339,0.00226173,0.0004825821,0.001637849,0.00005495235],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823236,0.009193742,0.002635732,0.0006457899,0.0004071381,0.001857869,0.001176077,0.00009902442,0.001660966],"genre_scores_gemma":[0.9929298,0.001836478,0.00193848,0.0005435839,0.0003046366,0.0008643641,0.0007618106,0.0000287101,0.0007920999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01891291,"threshold_uncertainty_score":0.1000223,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379509021","doi":"10.1007/s11523-023-00965-7","title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Insect Resistance and Genetics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Pharmacology; Adverse effect","authors":[{"name":"Todd M. Bauer","is_ca":false},{"name":"Kathleen N. Moore","is_ca":false},{"name":"Janet S. Rader","is_ca":false},{"name":"Fiona Simpkins","is_ca":false},{"name":"Alain C. Mita","is_ca":false},{"name":"J. Thaddeus Beck","is_ca":false},{"name":"Lowell L. Hart","is_ca":false},{"name":"Quincy S. Chu","is_ca":true},{"name":"Amit M. Oza","is_ca":true},{"name":"Anna V. Tinker","is_ca":false},{"name":"Esteban Rodrigo Imedio","is_ca":false},{"name":"Sanjeev Kumar","is_ca":false},{"name":"Ganesh Mugundu","is_ca":false},{"name":"Suzanne Jenkins","is_ca":false},{"name":"Juliann Chmielecki","is_ca":false},{"name":"Suzanne F. Jones","is_ca":false},{"name":"David R. Spigel","is_ca":false},{"name":"Siqing Fu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007141951924465786,"gpt":0.3043287191005847,"spread":0.2971867671761189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001301895,0.001063084,0.001705956,0.0003320964,0.0004312155,0.0008101175,0.0005652854,0.0007598918,0.003422021],"category_scores_gemma":[0.0006636727,0.0004177864,0.0009374303,0.0003973654,0.0006928348,0.0006523038,0.0002748957,0.002319595,0.0008923427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008054909,"about_ca_system_score_gemma":0.001833967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006661885,"about_ca_topic_score_gemma":0.001367033,"domain_scores_codex":[0.9996588,0.0001373418,0.00002194351,0.00006199325,0.00003765848,0.00008224638],"domain_scores_gemma":[0.9992756,0.00009354044,0.0001302193,0.00005979912,0.00004969208,0.0003911508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6225053,0.121964,0.0142733,0.001425575,0.001436378,0.0005186537,0.0004160728,0.003005425,0.1084762,0.0003070601,0.003729159,0.1219429],"study_design_scores_gemma":[0.2938319,0.6843798,0.01228022,0.00003305457,0.0003538246,0.0003875467,0.00006997832,0.000898512,0.004950139,0.0001392509,0.002656743,0.00001922036],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993811,0.001305836,0.0004107186,0.0001690748,0.0000692341,0.002182351,0.000718371,0.00004349329,0.001290027],"genre_scores_gemma":[0.9917167,0.001164102,0.00117236,0.000439547,0.0001089489,0.002014798,0.002015742,0.00001915327,0.00134866],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003422021,"threshold_uncertainty_score":0.01144779,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3157804315","doi":"10.1007/s11523-021-00813-6","title":"Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies","year":2021,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sumitomo Dainippon Pharma Oncology","keywords":"Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Phases of clinical research; Cancer; Dosing; Oncology; Clinical trial","authors":[{"name":"Alexander I. Spira","is_ca":false},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Wael A. Harb","is_ca":false},{"name":"Kelly K. Curtis","is_ca":false},{"name":"Erina Koga‐Yamakawa","is_ca":false},{"name":"Makoto Origuchi","is_ca":false},{"name":"Zhonggai Li","is_ca":false},{"name":"Bella Ertik","is_ca":false},{"name":"Walid L. Shaib","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01280117383212232,"gpt":0.3102873812325547,"spread":0.2974862074004324,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001674625,0.001371896,0.001803588,0.0003514761,0.0004194555,0.0008043415,0.0007682343,0.0008597132,0.002799239],"category_scores_gemma":[0.0009974807,0.0005036703,0.0007857566,0.0004342907,0.0008225353,0.000887725,0.0003536041,0.003069857,0.0008807833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006739605,"about_ca_system_score_gemma":0.001485116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004734383,"about_ca_topic_score_gemma":0.0007907862,"domain_scores_codex":[0.9995546,0.0001931401,0.00002628927,0.0000969208,0.00005460208,0.00007445959],"domain_scores_gemma":[0.9992893,0.0001119949,0.0001619981,0.00006929805,0.00005272878,0.0003145967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6180591,0.1379851,0.01582692,0.0007516209,0.001035839,0.0004150918,0.000611196,0.003877577,0.1028315,0.0002888168,0.004252036,0.1140652],"study_design_scores_gemma":[0.3465169,0.6325609,0.01211568,0.00001911448,0.0002708418,0.0002943759,0.00006289342,0.001337165,0.004446612,0.0001079601,0.002245216,0.00002221302],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950914,0.0008135884,0.0006073101,0.0001776456,0.00005803939,0.001701664,0.0005164462,0.00008205843,0.0009518324],"genre_scores_gemma":[0.9937412,0.0006358914,0.001569762,0.0003658718,0.0001417221,0.001502546,0.0009524024,0.00002405044,0.001066529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002799239,"threshold_uncertainty_score":0.009364426,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2985618399","doi":"10.1007/s11523-019-00689-7","title":"High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Breast cancer; Internal medicine; Mutation; Immunology; Cancer; Genetics; Gene","authors":[{"name":"Ioannis A. Voutsadakis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0226872329180317,"gpt":0.2912074542816495,"spread":0.2685202213636178,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001257934,0.0004341471,0.0005941591,0.0008204573,0.0003230547,0.001438455,0.000544699,0.0006953322,0.00309849],"category_scores_gemma":[0.004164294,0.0002616524,0.0005043751,0.001422473,0.0004301852,0.001064348,0.0005043189,0.001089216,0.0003675904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002315438,"about_ca_system_score_gemma":0.000385575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007664782,"about_ca_topic_score_gemma":0.001490673,"domain_scores_codex":[0.9995771,0.0001361597,0.00004200984,0.00009522306,0.00006714491,0.00008235675],"domain_scores_gemma":[0.9977487,0.0009389965,0.0008498026,0.0001366759,0.0001341355,0.0001916875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004288865,0.0000775912,0.9745083,0.00005349273,0.000259659,0.0001654075,0.00004114919,0.0003314085,0.001154397,0.0003052192,0.0005685289,0.02210589],"study_design_scores_gemma":[0.00002472583,0.0001745845,0.9907347,0.00005034371,0.0002987964,0.0008957175,0.0002607168,0.002655024,0.0006538577,0.001954729,0.002277103,0.00001959516],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750022,0.01785087,0.001480371,0.002533769,0.0001215956,0.00001076901,0.0006487782,0.0000470967,0.002304449],"genre_scores_gemma":[0.9955485,0.002465208,0.0006018638,0.0002034947,0.0002791288,0.000007182262,0.0003979746,0.00001094773,0.000485597],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00309849,"threshold_uncertainty_score":0.01036549,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061663237","doi":"10.1007/s11523-010-0143-8","title":"Prognostic and predictive biomarkers in renal cell carcinoma","year":2010,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Biomarker; Biomarker discovery; Kidney cancer; Vascular endothelial growth factor; Clear cell renal cell carcinoma; Oncology; Targeted therapy; Cancer; Pathology; Cancer research; Bioinformatics; Internal medicine; VEGF receptors; Proteomics; Biology; Gene","authors":[{"name":"Michael M. Vickers","is_ca":true},{"name":"Daniel Y.C. Heng","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03238352251163952,"gpt":0.3148014887375521,"spread":0.2824179662259126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001499425,0.001186164,0.002973292,0.002364832,0.0002343826,0.001421961,0.001213038,0.001031435,0.001542608],"category_scores_gemma":[0.002350118,0.0004399014,0.001036305,0.003046957,0.0005775773,0.001482071,0.0006474347,0.002004941,0.0007683391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009511535,"about_ca_system_score_gemma":0.001882896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001930119,"about_ca_topic_score_gemma":0.003072279,"domain_scores_codex":[0.9996291,0.00007507309,0.00007470457,0.00006446413,0.000129287,0.00002730296],"domain_scores_gemma":[0.9989428,0.0005601295,0.000225625,0.00002442245,0.0002098496,0.00003719258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001558586,0.00006853246,0.001032802,0.01922125,0.0004072422,0.0001418497,0.00003415671,0.000522587,0.0005856407,0.001705018,0.02417222,0.9519528],"study_design_scores_gemma":[0.0001758028,0.0004022809,0.007806663,0.0194389,0.003365725,0.00248956,0.0001586121,0.0008630346,0.001380355,0.00481084,0.9590099,0.00009845479],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001052324,0.9991755,0.0001127059,0.0002290095,0.0001024713,0.000003993253,0.0000260593,0.000004151332,0.0002407251],"genre_scores_gemma":[0.001180849,0.9979074,0.0002206294,0.0002429205,0.0001753044,0.000006236462,0.00005364958,0.000001050766,0.0002120753],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002973292,"threshold_uncertainty_score":0.007929862,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2076911447","doi":"10.1007/s11523-013-0299-0","title":"Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Bayer HealthCare","keywords":"Medicine; Liter; Sorafenib; Placental growth factor; Internal medicine; Vascular endothelial growth factor; Endoglin; VEGF receptors; Angiosarcoma; Gastroenterology; Hepatocellular carcinoma; Pathology; Stem cell; CD34","authors":[{"name":"Nicolas Penel","is_ca":false},{"name":"Isabelle Ray‐Coquard","is_ca":false},{"name":"Christine Bal-Mahieu","is_ca":false},{"name":"Christine Chevreau","is_ca":false},{"name":"Axel Le Cesne","is_ca":false},{"name":"Antoîne Italiano","is_ca":false},{"name":"Emmanuelle Bompas","is_ca":false},{"name":"Stéphanie Clisant","is_ca":false},{"name":"Brigitte Baldeyrou","is_ca":false},{"name":"Amélie Lansiaux","is_ca":false},{"name":"Y Robin","is_ca":false},{"name":"Jacques‐Olivier Bay","is_ca":false},{"name":"Sophie Piperno‐Neumann","is_ca":false},{"name":"Jean‐Yves Blay","is_ca":false},{"name":"Charles Fournier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04767621424879121,"gpt":0.305364035680701,"spread":0.2576878214319098,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001502552,0.0008530733,0.001234384,0.0002210603,0.000304989,0.0009883619,0.0003274232,0.0005873649,0.001566996],"category_scores_gemma":[0.001436927,0.0002791244,0.001278403,0.0003622855,0.0005321172,0.0006977647,0.0002975417,0.001590279,0.0002549495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003292355,"about_ca_system_score_gemma":0.0004487566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002382855,"about_ca_topic_score_gemma":0.0004862827,"domain_scores_codex":[0.9995713,0.0001882671,0.00003203089,0.00008967098,0.00004725874,0.00007138205],"domain_scores_gemma":[0.9987363,0.0003766167,0.0003824015,0.000100435,0.0000688071,0.0003354332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5175599,0.01491066,0.329328,0.0006061723,0.007188479,0.0004923953,0.0002897762,0.002278815,0.04909551,0.0002505796,0.002315389,0.07568419],"study_design_scores_gemma":[0.08836798,0.2351715,0.6539003,0.00006189727,0.005564035,0.001472165,0.0002978042,0.003909445,0.006352016,0.0007684152,0.004007282,0.0001272251],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988602,0.0005053699,0.0001143747,0.00008121341,0.00003287878,0.00004512127,0.0001613879,0.000007475792,0.0001919406],"genre_scores_gemma":[0.9982225,0.000293315,0.0002357585,0.0001459929,0.00008771933,0.00006641216,0.0006087265,0.00000501567,0.0003345305],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001566996,"threshold_uncertainty_score":0.007946372,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2743780916","doi":"10.1007/s11523-017-0525-2","title":"A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Ipsen","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Cancer; Sorafenib; Nausea; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Phases of clinical research","authors":[{"name":"Bernard Escudier","is_ca":false},{"name":"Sandrine Faivre","is_ca":false},{"name":"Eric Van Cutsem","is_ca":false},{"name":"N. Germann","is_ca":false},{"name":"Jean-Christophe Pouget","is_ca":false},{"name":"Ruth Plummer","is_ca":false},{"name":"Ignace Vergote","is_ca":false},{"name":"Fiona Thistlethwaite","is_ca":false},{"name":"Georg A. Bjarnason","is_ca":true},{"name":"Robert J. Jones","is_ca":false},{"name":"Helen Mackay","is_ca":true},{"name":"Julien Edeline","is_ca":false},{"name":"Lætitia Fartoux","is_ca":false},{"name":"Hal W. Hirte","is_ca":true},{"name":"Amit M. Oza","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03434511081770929,"gpt":0.3299875841284284,"spread":0.2956424733107191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002126866,0.001311183,0.002352137,0.0003587905,0.0004376092,0.001413125,0.0008972649,0.001268155,0.003207198],"category_scores_gemma":[0.0007760722,0.000638417,0.001821881,0.0003849411,0.001335553,0.001155517,0.0003425817,0.00374631,0.000708312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001348246,"about_ca_system_score_gemma":0.001817575,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001277559,"about_ca_topic_score_gemma":0.003288072,"domain_scores_codex":[0.9995436,0.0001666137,0.00001589545,0.00009931335,0.00004994303,0.0001246769],"domain_scores_gemma":[0.999433,0.00008153734,0.00008132138,0.00007846837,0.00005653272,0.0002691868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6049904,0.07471386,0.005254392,0.002433009,0.004039969,0.0003991645,0.0006347492,0.006020122,0.166898,0.001261826,0.009622013,0.1237324],"study_design_scores_gemma":[0.4344356,0.5306541,0.007858711,0.00007365006,0.001365584,0.0004696604,0.0002635366,0.002439938,0.01261228,0.0006976856,0.009049976,0.00007930207],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987334,0.003301356,0.002489737,0.0007533475,0.0003592997,0.002844517,0.001217243,0.0001526581,0.001547826],"genre_scores_gemma":[0.9849125,0.002718845,0.00388009,0.001218996,0.0001540799,0.002409394,0.00170259,0.00006477558,0.002938782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003207198,"threshold_uncertainty_score":0.01124811,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","authors":[{"name":"Christian Kollmannsberger","is_ca":false},{"name":"Herbert I. Hurwitz","is_ca":false},{"name":"Lyudmila Bazhenova","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false},{"name":"David S. Hong","is_ca":false},{"name":"Keunchil Park","is_ca":false},{"name":"Karen L. Reckamp","is_ca":false},{"name":"Sunil Sharma","is_ca":false},{"name":"Hirak Der‐Torossian","is_ca":false},{"name":"James G. Christensen","is_ca":false},{"name":"Demiana Faltaos","is_ca":false},{"name":"Diane Potvin","is_ca":true},{"name":"Vanessa Tassell","is_ca":false},{"name":"Richard C. Chao","is_ca":false},{"name":"Geoffrey I. Shapiro","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01739782352627714,"gpt":0.3924252135381065,"spread":0.3750273900118293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001028248,0.00149566,0.001921895,0.0003807507,0.0003978983,0.001127387,0.0007596466,0.001068767,0.003216608],"category_scores_gemma":[0.0005784453,0.0005876385,0.001714731,0.0004428407,0.0007839818,0.0007262463,0.00033781,0.003519338,0.0007485802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133886,"about_ca_system_score_gemma":0.001904595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002689654,"about_ca_topic_score_gemma":0.008505329,"domain_scores_codex":[0.9997564,0.00009235429,0.000009250109,0.00004812122,0.0000201641,0.00007370201],"domain_scores_gemma":[0.9995314,0.00006065944,0.00006512235,0.00002471315,0.00002596445,0.0002920834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7593347,0.06410749,0.008784422,0.001091832,0.002854391,0.0004317677,0.0003159398,0.00702561,0.048992,0.0007069671,0.01079695,0.09555792],"study_design_scores_gemma":[0.6471391,0.3288106,0.01386907,0.00004530395,0.0008350133,0.0003460529,0.0001044306,0.001990606,0.00280202,0.0003121787,0.00370711,0.00003851135],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887862,0.002854874,0.0005748678,0.0009224809,0.0002127912,0.001763471,0.001997317,0.0001166162,0.002771394],"genre_scores_gemma":[0.9845341,0.003081286,0.001498782,0.001330432,0.0001745368,0.001390495,0.004373681,0.00004246159,0.003574138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003216608,"threshold_uncertainty_score":0.01076061,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3092483376","doi":"10.1007/s11523-020-00748-4","title":"Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"Amgen","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; Clinical endpoint; Confidence interval; CD20; Randomized controlled trial; Lymphoma; Gastroenterology; Ofatumumab; Oncology","authors":[{"name":"Dietger Niederwieser","is_ca":false},{"name":"Caroline Hamm","is_ca":true},{"name":"Patrick Cobb","is_ca":false},{"name":"Mindy Mo","is_ca":false},{"name":"Cecily Forsyth","is_ca":false},{"name":"Alessandra Tucci","is_ca":false},{"name":"Vladimir Hanes","is_ca":false},{"name":"Vincent Delwail","is_ca":false},{"name":"Roman Hájek","is_ca":false},{"name":"David Chien","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03036682753850691,"gpt":0.2829847304425309,"spread":0.252617902904024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002383112,0.0007160791,0.00172746,0.0003292393,0.0002734733,0.0008523831,0.000632923,0.001110939,0.002144434],"category_scores_gemma":[0.002532324,0.000301874,0.001221782,0.0003962517,0.0007720542,0.0009606773,0.0003899011,0.001495223,0.0004050064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007414455,"about_ca_system_score_gemma":0.0006825133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003179313,"about_ca_topic_score_gemma":0.0005639241,"domain_scores_codex":[0.9988887,0.0006759794,0.00009871362,0.000138782,0.0001210801,0.00007675605],"domain_scores_gemma":[0.9985055,0.0004255158,0.0005317016,0.0001249939,0.00009806624,0.0003142981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9364923,0.002774459,0.01007596,0.0009620585,0.002960179,0.0001175356,0.0001326549,0.0004998736,0.006526176,0.0001162349,0.0007840233,0.03855856],"study_design_scores_gemma":[0.6715454,0.24228,0.07190725,0.0002665473,0.005840791,0.0005075013,0.0001584356,0.001398351,0.002157895,0.0004854576,0.003373988,0.00007840565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943473,0.004212312,0.00006729186,0.0002909228,0.0000517797,0.0001177282,0.0002564791,0.00001419485,0.0006419418],"genre_scores_gemma":[0.9963601,0.00147634,0.0002360077,0.000389233,0.0001814125,0.0002804952,0.0005895139,0.000008980504,0.0004778942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002383112,"threshold_uncertainty_score":0.01260328,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2962334030","doi":"10.1007/s11523-019-00652-6","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Adenocarcinoma; Internal medicine; Resistance mutation; Cancer; Cancer research; Gefitinib; Erlotinib; Gene; Biology; Genetics; Polymerase chain reaction","authors":[{"name":"Zhe Yang","is_ca":false},{"name":"Jinqi Yang","is_ca":false},{"name":"Yedan Chen","is_ca":false},{"name":"Yang Shao","is_ca":true},{"name":"Xing Wang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01104115390947608,"gpt":0.329290657629553,"spread":0.3182495037200769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002116344,0.000300801,0.0003904467,0.0005693009,0.0007820491,0.0008201739,0.0003745226,0.001334565,0.004057133],"category_scores_gemma":[0.0007983647,0.0002037045,0.0004675343,0.0004038702,0.0004393328,0.0006014543,0.0002589969,0.001037327,0.000482716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005985778,"about_ca_system_score_gemma":0.0004638019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001666458,"about_ca_topic_score_gemma":0.002409236,"domain_scores_codex":[0.9998116,0.00002053857,0.00002111352,0.00004407516,0.00003475312,0.00006797475],"domain_scores_gemma":[0.9997323,0.00007825434,0.00006289059,0.00001575828,0.00002694307,0.00008380043],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"case_report","study_design_scores_codex":[0.00135082,0.000359961,0.6571401,0.00006756806,0.00009268892,0.298349,0.0004599371,0.0007012622,0.01593488,0.001653915,0.003691678,0.02019818],"study_design_scores_gemma":[0.0001197623,0.0008664018,0.3686815,0.00008097534,0.0003117604,0.6078283,0.001329427,0.005685387,0.007004545,0.002198916,0.005835886,0.00005710006],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927877,0.000624124,0.0002150145,0.001101922,0.00003824114,0.000017325,0.0002333205,0.00001543796,0.004967049],"genre_scores_gemma":[0.9989709,0.0001380986,0.0001416442,0.0002139919,0.0000414705,0.000002180565,0.00007795201,0.000005086936,0.0004086535],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004057133,"threshold_uncertainty_score":0.01357245,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387930721","doi":"10.1007/s11523-023-00997-z","title":"A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Cetuximab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Head and neck cancer; Phases of clinical research; Cancer; Clinical trial; Colorectal cancer","authors":[{"name":"Albiruni Ryan Abdul Razak","is_ca":true},{"name":"Hung‐Ming Wang","is_ca":false},{"name":"Jang‐Yang Chang","is_ca":false},{"name":"Myung‐Ju Ahn","is_ca":false},{"name":"Pamela N. Münster","is_ca":false},{"name":"George R. Blumenschein","is_ca":false},{"name":"Benjamin Solomon","is_ca":false},{"name":"Wan‐Teck Lim","is_ca":false},{"name":"Ruey‐Long Hong","is_ca":false},{"name":"David G. Pfister","is_ca":false},{"name":"Nabil F. Saba","is_ca":false},{"name":"Se‐Hoon Lee","is_ca":false},{"name":"Carla van Herpen","is_ca":false},{"name":"Cornelia Quadt","is_ca":false},{"name":"Douglas Bootle","is_ca":false},{"name":"Lars Blumenstein","is_ca":false},{"name":"David Demanse","is_ca":false},{"name":"Jean‐Pierre Delord","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03311622994514312,"gpt":0.3371139118074929,"spread":0.3039976818623498,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002992564,0.001959902,0.003463135,0.0006604232,0.0004589886,0.001113272,0.0009248921,0.001718938,0.005276326],"category_scores_gemma":[0.001579144,0.00104718,0.002899664,0.000568757,0.0008671217,0.001008265,0.0004593615,0.003065949,0.001215549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219467,"about_ca_system_score_gemma":0.001930073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001323218,"about_ca_topic_score_gemma":0.00296011,"domain_scores_codex":[0.9989287,0.000596968,0.00004921587,0.0001890007,0.000103788,0.0001323219],"domain_scores_gemma":[0.9990446,0.0001614351,0.0002194087,0.00009131926,0.00009895771,0.0003843358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8434001,0.05909966,0.004920468,0.001698412,0.002635973,0.0002672973,0.0002711865,0.00166018,0.02537897,0.0001328683,0.002324727,0.05821006],"study_design_scores_gemma":[0.6600773,0.3263806,0.008956816,0.00003772228,0.0007471063,0.0001826363,0.00003589311,0.0007370047,0.001299521,0.00007473258,0.001438554,0.00003213773],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871802,0.004829042,0.0005971409,0.0006666494,0.0001816696,0.004315708,0.0009094962,0.000104637,0.001215386],"genre_scores_gemma":[0.9837646,0.003892373,0.002047202,0.00102528,0.0002606797,0.004218962,0.001889793,0.00004655642,0.002854514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005276326,"threshold_uncertainty_score":0.01765108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3095962378","doi":"10.1007/s11523-020-00770-6","title":"Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Everolimus; Exemestane; Oncology; Internal medicine; Hazard ratio; Breast cancer; Odds ratio; Metastatic breast cancer; Meta-analysis; Confidence interval; Cancer; Aromatase","authors":[{"name":"Jacques Raphael","is_ca":true},{"name":"Cory Lefebvre","is_ca":true},{"name":"Alison L. Allan","is_ca":true},{"name":"Joelle Helou","is_ca":true},{"name":"Gabriel Boldt","is_ca":true},{"name":"Theodore A. Vandenberg","is_ca":true},{"name":"Phillip Blanchette","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06320616612665578,"gpt":0.4072449643067012,"spread":0.3440387981800455,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005441783,0.002309907,0.01362516,0.003305711,0.0004579552,0.002338,0.001793716,0.001952174,0.005259131],"category_scores_gemma":[0.01276058,0.001274743,0.02194486,0.005440428,0.0005482903,0.00183462,0.001737203,0.001914918,0.0004460481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00155622,"about_ca_system_score_gemma":0.002432972,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005691317,"about_ca_topic_score_gemma":0.02243822,"domain_scores_codex":[0.9964961,0.001447386,0.001032083,0.000440518,0.0004005227,0.0001833711],"domain_scores_gemma":[0.994786,0.003445443,0.001146332,0.000186507,0.0003344997,0.0001011973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.002063305,0.00003215082,0.00312134,0.4558829,0.520445,0.0001349541,0.00009595462,0.0004086736,0.0003294454,0.0001508083,0.0009529988,0.01638232],"study_design_scores_gemma":[0.0007919766,0.0001410843,0.003139838,0.02026928,0.9727936,0.00009525796,0.00005212344,0.0001163658,0.00007571637,0.0001692487,0.002329701,0.00002597446],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003177157,0.9956248,0.0003239917,0.0001103425,0.0000877686,0.000105249,0.0003824896,0.0000175735,0.0001706084],"genre_scores_gemma":[0.107558,0.8882884,0.001671076,0.0009752072,0.0001642022,0.0003522811,0.0005375579,0.00002951134,0.0004238031],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01362516,"threshold_uncertainty_score":0.02877927,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973375841","doi":"10.1007/s11523-009-0120-2","title":"Nuclear imaging of molecular processes in cancer","year":2009,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Thomas Hospital","funders":"University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Molecular imaging; Medicine; Positron emission tomography; Nuclear medicine; Nuclear imaging; Pet imaging; Medical physics; Cancer; Internal medicine; In vivo; Biology; Biotechnology","authors":[{"name":"Rafael T. M. de Rosales","is_ca":true},{"name":"Erik Årstad","is_ca":false},{"name":"Philip J. Blower","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04336537521571856,"gpt":0.424973262258337,"spread":0.3816078870426185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009625449,0.001459302,0.001646235,0.002919959,0.0003400928,0.001129208,0.00122861,0.001706921,0.003267942],"category_scores_gemma":[0.001089155,0.0005709733,0.0004724589,0.002888926,0.001209859,0.00195477,0.0009071105,0.001881734,0.002612817],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001015334,"about_ca_system_score_gemma":0.001391222,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002006159,"about_ca_topic_score_gemma":0.003393087,"domain_scores_codex":[0.9997795,0.00004755421,0.00002570831,0.00003809405,0.00008546413,0.00002360684],"domain_scores_gemma":[0.999392,0.0003428523,0.00007609979,0.0000190184,0.0001376836,0.00003221979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001214467,0.00008133287,0.0001408694,0.01533978,0.00007757587,0.0003910433,0.00008140798,0.0005919668,0.005682703,0.00437286,0.03361234,0.9395066],"study_design_scores_gemma":[0.00002513848,0.00009051187,0.0003452127,0.002195214,0.000104199,0.002397267,0.00005373146,0.0001666148,0.002202444,0.001511209,0.9908805,0.00002789612],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000925752,0.9980485,0.000371303,0.0001639216,0.0001700713,0.000006092438,0.00000856631,0.000008482916,0.001130476],"genre_scores_gemma":[0.0006471429,0.9977298,0.0004248764,0.0001655597,0.000164402,0.000007018181,0.00001573051,0.000002249216,0.0008431541],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003267942,"threshold_uncertainty_score":0.01093239,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172387625","doi":"10.1007/s11523-021-00822-5","title":"Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Meta-analysis; Oncology; Targeted therapy; Clinical trial; Internal medicine; Pediatric oncology; Intensive care medicine; Cancer","authors":[{"name":"Karolina Strzebońska","is_ca":false},{"name":"Mateusz T. Wasylewski","is_ca":false},{"name":"Łucja Zaborowska","is_ca":false},{"name":"Maciej Polak","is_ca":false},{"name":"Emilia Sługocka","is_ca":false},{"name":"Jakub Straś","is_ca":false},{"name":"Mateusz Blukacz","is_ca":false},{"name":"Bishal Gyawali","is_ca":true},{"name":"Marcin Waligóra","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.7192358579784843,"gpt":0.652057374042999,"spread":0.06717848393548531,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03423872,0.003305393,0.02251593,0.008481128,0.0006836707,0.004010059,0.002432824,0.002531352,0.003694382],"category_scores_gemma":[0.07986587,0.001896014,0.05429957,0.009739842,0.001067012,0.003134055,0.001990169,0.002446967,0.0003401859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003149221,"about_ca_system_score_gemma":0.003522711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004288611,"about_ca_topic_score_gemma":0.008871377,"domain_scores_codex":[0.9658879,0.01935524,0.008714155,0.002648368,0.002836454,0.000557907],"domain_scores_gemma":[0.922038,0.06309611,0.009804789,0.001869502,0.002690835,0.0005007108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001774983,0.00001627522,0.00415546,0.2421216,0.7439942,0.0001032152,0.00006169975,0.0006127778,0.0001098043,0.0001515776,0.0004746297,0.006423736],"study_design_scores_gemma":[0.000690057,0.0001408687,0.002346681,0.0174941,0.9777115,0.00006874009,0.00003163472,0.0002768496,0.00006174415,0.0002857911,0.0008718589,0.00002023915],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005487558,0.9906238,0.001728114,0.0002954484,0.0001736504,0.000664566,0.0006684819,0.000042877,0.0003155268],"genre_scores_gemma":[0.3210655,0.661735,0.008035656,0.001696145,0.0005416544,0.004948238,0.001396307,0.00008329005,0.0004982355],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03423872,"threshold_uncertainty_score":0.1810738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4393260725","doi":"10.1007/s11523-024-01046-z","title":"Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Breast cancer; Randomized controlled trial; Population; Metastatic breast cancer; Clinical trial; Oncology; Internal medicine; Cochrane Library; Cancer","authors":[{"name":"Étienne Brain","is_ca":false},{"name":"Connie Chen","is_ca":false},{"name":"Sofia Simon","is_ca":false},{"name":"Vinay Pasupuleti","is_ca":false},{"name":"Kathleen Vieira Pfitzer","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01904652755948039,"gpt":0.3726052928173543,"spread":0.3535587652578739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005906344,0.0012231,0.007695061,0.008554496,0.000528075,0.001906129,0.001459834,0.001630136,0.003914963],"category_scores_gemma":[0.02136611,0.0008122652,0.006108284,0.008924639,0.0006775371,0.001928357,0.001098688,0.0009024505,0.0002735417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003114877,"about_ca_system_score_gemma":0.008915592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007746515,"about_ca_topic_score_gemma":0.02345481,"domain_scores_codex":[0.9958895,0.001327442,0.001582575,0.0003168529,0.0007356373,0.000148186],"domain_scores_gemma":[0.9836187,0.01065129,0.003864631,0.0001717784,0.001449655,0.000243916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0002356956,0.00001575922,0.0008147305,0.9684466,0.0082646,0.0000850064,0.00009645475,0.00006045554,0.000105917,0.00009402452,0.001135551,0.02064524],"study_design_scores_gemma":[0.0005981581,0.0003205755,0.006032343,0.8699155,0.1061233,0.0005287977,0.0002528573,0.0001222564,0.0001614824,0.0002367346,0.0156714,0.00003666893],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001111522,0.9977973,0.00006914201,0.0001952223,0.00005568193,0.0002669222,0.000270955,0.000005191935,0.0002281703],"genre_scores_gemma":[0.01862459,0.979426,0.0003918828,0.0005912774,0.0000805182,0.0005652096,0.0002096018,0.000003588246,0.0001073523],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008554496,"threshold_uncertainty_score":0.03123611,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2957412264","doi":"10.1007/s11523-019-00654-4","title":"A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"Meningioma Mommas","keywords":"Medicine; Integrin; Meningioma; Monoclonal antibody; Cancer research; Protein kinase B; Laminin; In vivo; In vitro; Pathology; Antibody; Cell; Phosphorylation; Immunology; Internal medicine; Biology; Receptor; Cell biology","authors":[{"name":"Fares Nigim","is_ca":false},{"name":"Juri Kiyokawa","is_ca":false},{"name":"Alessandra Gurtner","is_ca":false},{"name":"Yoichiro Kawamura","is_ca":false},{"name":"Lingyang Hua","is_ca":false},{"name":"Ekkehard M. Kasper","is_ca":true},{"name":"Priscilla K. Brastianos","is_ca":false},{"name":"Daniel P. Cahill","is_ca":false},{"name":"Samuel D. Rabkin","is_ca":false},{"name":"Robert L. Martuza","is_ca":false},{"name":"W. Shawn Carbonell","is_ca":false},{"name":"Hiroaki Wakimoto","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02769570325496929,"gpt":0.3088989663630577,"spread":0.2812032631080885,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001012995,0.0003045671,0.0002180769,0.0002467299,0.0001740277,0.0002480219,0.0001960919,0.0002255387,0.0009490317],"category_scores_gemma":[0.00006288225,0.000103477,0.0002018065,0.0001664211,0.0001351172,0.0001446413,0.00007591547,0.000590789,0.0001917503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002559928,"about_ca_system_score_gemma":0.0002424521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001341751,"about_ca_topic_score_gemma":0.002773826,"domain_scores_codex":[0.999918,0.00001054839,0.000004264585,0.000009440835,0.00001827771,0.00003948132],"domain_scores_gemma":[0.9999462,0.00001011896,0.00001279077,0.000005486057,0.000005399016,0.00002001334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006770536,0.0005734895,0.000230239,0.00004097127,0.00001691504,0.00008964915,0.00002481391,0.0002547736,0.9948093,0.0001496941,0.0002129536,0.002920195],"study_design_scores_gemma":[0.0001276092,0.004871029,0.004975823,0.000008802358,0.00006806514,0.0003858573,0.00008481796,0.001906927,0.9852108,0.00007397093,0.002279989,0.000006211556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971289,0.0006795561,0.0006275494,0.0001015687,0.00004900806,0.00001128504,0.00008158998,0.00003593427,0.001284537],"genre_scores_gemma":[0.9966339,0.0006966565,0.0005645695,0.00003024764,0.00001201542,0.00001284712,0.0001784188,0.000007313294,0.001863996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001341751,"threshold_uncertainty_score":0.003174782,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366351020","doi":"10.1007/s11523-023-00957-7","title":"Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Palbociclib; Targeted therapy; Chemotherapy; Cyclin-dependent kinase 4; Cancer; Clinical trial; Cell cycle; Cyclin-dependent kinase 2","authors":[{"name":"Melody Zhao","is_ca":true},{"name":"Kent A. Hanson","is_ca":false},{"name":"Yixie Zhang","is_ca":true},{"name":"Anna Zhou","is_ca":true},{"name":"Ashley S. Cha-Silva","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03738858245496208,"gpt":0.3918227242008502,"spread":0.3544341417458882,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003084362,0.001047294,0.003552692,0.01042801,0.0004847493,0.002056062,0.001396242,0.001806616,0.004231306],"category_scores_gemma":[0.01014508,0.0006262527,0.002901756,0.01221354,0.0005386778,0.002434754,0.001065444,0.001159102,0.0006451657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002393554,"about_ca_system_score_gemma":0.007270555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004639842,"about_ca_topic_score_gemma":0.009005884,"domain_scores_codex":[0.9977717,0.0005762371,0.0009143932,0.0001904968,0.0004435422,0.0001035863],"domain_scores_gemma":[0.9906868,0.006184435,0.001548077,0.0001159806,0.001317624,0.0001470858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002010765,0.0000535181,0.0005355667,0.7125571,0.001271137,0.0003231352,0.0003574182,0.0002380739,0.0005708071,0.001317982,0.01312137,0.2694528],"study_design_scores_gemma":[0.00009078503,0.0002178104,0.002774384,0.7955472,0.01133947,0.001308377,0.0004353059,0.0001147453,0.0002869258,0.0009587787,0.1868907,0.0000354242],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001795237,0.998922,0.000053361,0.0003213694,0.0001519425,0.00002575165,0.00005674715,0.000003024634,0.0002863929],"genre_scores_gemma":[0.001311477,0.9978169,0.0001624622,0.0004254459,0.0001100802,0.00003630724,0.00005285525,0.000001567609,0.00008285455],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01042801,"threshold_uncertainty_score":0.01736659,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","authors":[{"name":"Abdulazeez Salawu","is_ca":true},{"name":"Aaron R. Hansen","is_ca":true},{"name":"Anna Spreafico","is_ca":true},{"name":"Esmail Mutahar Al-Ezzi","is_ca":true},{"name":"Sheila Webster","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Jeffrey Doi","is_ca":true},{"name":"Lisa Wang","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Albiruni R. Abdul Razak","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06037269198487216,"gpt":0.3976504848924063,"spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001264784,0.001998823,0.002568887,0.0003875295,0.0004541204,0.001369371,0.0007717924,0.001695233,0.00498678],"category_scores_gemma":[0.001160012,0.0004913054,0.002062435,0.0005177255,0.0008146584,0.001530319,0.0005518369,0.003559579,0.001125587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106326,"about_ca_system_score_gemma":0.001302072,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162584,"about_ca_topic_score_gemma":0.003764124,"domain_scores_codex":[0.9996411,0.0001265681,0.00001679827,0.00007114495,0.00003029701,0.0001140886],"domain_scores_gemma":[0.9994307,0.00009215496,0.0000985929,0.00004626071,0.00003706455,0.0002951826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8093213,0.01144181,0.00713887,0.001061236,0.004311147,0.0006521191,0.0003297267,0.00516824,0.02885765,0.001559971,0.01634507,0.1138129],"study_design_scores_gemma":[0.8844901,0.09604952,0.00793211,0.0000491217,0.0008985724,0.0006580796,0.0001192208,0.001498232,0.001749624,0.001389327,0.005086343,0.00007971885],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859722,0.003088205,0.0007900615,0.002469093,0.0003508948,0.001015701,0.002766036,0.0001621748,0.003385646],"genre_scores_gemma":[0.9852399,0.00261724,0.001512653,0.002054294,0.0001715953,0.001187861,0.003737564,0.0000763268,0.003402606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00498678,"threshold_uncertainty_score":0.01668251,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789468111","doi":"10.1007/s11523-018-0559-0","title":"Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Ipsen; Canadian Centre for Applied Research in Cancer Control","keywords":"Cabozantinib; Medicine; Sunitinib; Internal medicine; Sorafenib; Oncology; Hazard ratio; Renal cell carcinoma; Meta-analysis; Bevacizumab; Temsirolimus; Progression-free survival; Subgroup analysis; Confidence interval; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","authors":[{"name":"Elvira Schmidt","is_ca":false},{"name":"J. Lister","is_ca":false},{"name":"Monika Neumann","is_ca":false},{"name":"Witold Więcek","is_ca":false},{"name":"Shuai Fu","is_ca":false},{"name":"A.L. Vataire","is_ca":false},{"name":"Jelena Sostar","is_ca":false},{"name":"Shengnan Huang","is_ca":false},{"name":"Florence Marteau","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1109176175775262,"gpt":0.3834524545767004,"spread":0.2725348369991741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01326933,0.002106196,0.01502668,0.005170755,0.0004756994,0.002403864,0.001761629,0.00169882,0.002621916],"category_scores_gemma":[0.02525306,0.0009984529,0.03249329,0.005039173,0.0005977717,0.001402389,0.001152392,0.001497226,0.0002085181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002875033,"about_ca_system_score_gemma":0.002936114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006892249,"about_ca_topic_score_gemma":0.01571006,"domain_scores_codex":[0.9905292,0.005299923,0.002129673,0.0008954434,0.0009271012,0.0002185884],"domain_scores_gemma":[0.9841573,0.01149651,0.002824371,0.0003757801,0.000920394,0.0002257528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.004264947,0.00004300761,0.003221062,0.3014999,0.6779147,0.00008183015,0.00006287516,0.0007035677,0.0002194611,0.0001387933,0.0004235854,0.01142627],"study_design_scores_gemma":[0.001320791,0.000297344,0.002632643,0.01621874,0.9777849,0.00005843081,0.00002778804,0.0002916399,0.00008878293,0.0001843285,0.001077439,0.00001715893],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008838572,0.9889542,0.0005613591,0.0002177402,0.0001391125,0.0003877537,0.0005423909,0.00002560206,0.0003333171],"genre_scores_gemma":[0.3506927,0.6421093,0.003054278,0.001035813,0.0002504005,0.001398467,0.001116494,0.00003353655,0.0003090232],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9849733,"threshold_uncertainty_score":0.07017577,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2735753765","doi":"10.1007/s11523-017-0516-3","title":"A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Testosterone (patch); Internal medicine; White blood cell; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Prospective cohort study; Proportional hazards model; Gastroenterology; Urology; Complete blood count; Cancer; Lymphocyte; Confidence interval; Oncology; Toxicity; Neutropenia","authors":[{"name":"Daniel Taussky","is_ca":true},{"name":"Denis Soulières","is_ca":true},{"name":"Laurent Azoulay","is_ca":true},{"name":"Hui Yin","is_ca":true},{"name":"Houda Bahig","is_ca":true},{"name":"Jean-Paul Bahary","is_ca":true},{"name":"Guila Delouya","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0143465471483212,"gpt":0.2977672131610162,"spread":0.2834206660126951,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001244832,0.0006281661,0.001081467,0.001016825,0.0003468605,0.001200741,0.0004003125,0.0004124097,0.0007554042],"category_scores_gemma":[0.002608853,0.0002272313,0.0005836101,0.001500569,0.0003601041,0.0004960425,0.000271051,0.0007180811,0.0002064823],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002873227,"about_ca_system_score_gemma":0.0007119197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001302112,"about_ca_topic_score_gemma":0.002625534,"domain_scores_codex":[0.9994857,0.0002344325,0.0000461475,0.00005402805,0.0001137247,0.00006603972],"domain_scores_gemma":[0.9984484,0.0005537745,0.0004194349,0.00007166631,0.0001396032,0.0003671494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002921089,0.0001682825,0.9739769,0.00006105183,0.0004389408,0.0002022309,0.00005388483,0.0007001866,0.002295071,0.00004447451,0.0003377245,0.01880017],"study_design_scores_gemma":[0.00008075395,0.001998976,0.9886854,0.00003412731,0.001226241,0.0007986167,0.0002220485,0.004491294,0.001193734,0.0002627452,0.0009720963,0.00003393676],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865888,0.0109234,0.0006151225,0.0003482725,0.0001733668,0.00001120414,0.0002303384,0.0000529257,0.001056639],"genre_scores_gemma":[0.9985203,0.0006906591,0.0002513307,0.00005553331,0.0001589037,0.000002818829,0.0001185234,0.000004160472,0.000197792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001302112,"threshold_uncertainty_score":0.006583333,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","authors":[{"name":"Erika Hamilton","is_ca":false},{"name":"Gerald S. Falchook","is_ca":false},{"name":"Judy S. Wang","is_ca":false},{"name":"Siqing Fu","is_ca":false},{"name":"Amit M. Oza","is_ca":true},{"name":"Esteban Rodrigo Imedio","is_ca":false},{"name":"Sanjeev Kumar","is_ca":false},{"name":"Lone H. Ottesen","is_ca":false},{"name":"Ganesh Mugundu","is_ca":false},{"name":"Elza C. de Bruin","is_ca":false},{"name":"Mark J. O’Connor","is_ca":false},{"name":"Suzanne F. Jones","is_ca":false},{"name":"David R. Spigel","is_ca":false},{"name":"Bob T. Li","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04736721586451495,"gpt":0.3932493215087382,"spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192162,0.001407957,0.002082554,0.0004311732,0.0004215504,0.001302325,0.0008467949,0.001208111,0.003109382],"category_scores_gemma":[0.0007476656,0.0005472257,0.001314941,0.0005203362,0.0008999436,0.001058017,0.000354398,0.00320278,0.0008201802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008900537,"about_ca_system_score_gemma":0.001405193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005591455,"about_ca_topic_score_gemma":0.001427198,"domain_scores_codex":[0.9996663,0.0001341026,0.00002301446,0.00006718856,0.0000363659,0.00007299596],"domain_scores_gemma":[0.9993001,0.0001304116,0.0001092789,0.00005084685,0.00003494303,0.0003744552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8169699,0.04396749,0.0047403,0.0009252232,0.001157161,0.000307513,0.0002691955,0.002643741,0.02350623,0.0002355334,0.003839758,0.1014379],"study_design_scores_gemma":[0.8155403,0.1739563,0.005356362,0.0000377924,0.0002302846,0.0002670546,0.00003850847,0.001292368,0.001346966,0.0002028924,0.001706762,0.00002445153],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923689,0.002704868,0.0003230239,0.0004404456,0.0001299763,0.00138252,0.0007665547,0.00009731662,0.001786323],"genre_scores_gemma":[0.9915497,0.001811714,0.00103807,0.0008978263,0.0002332619,0.001286778,0.001718158,0.00002451422,0.001439986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003109382,"threshold_uncertainty_score":0.01040196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989651221","doi":"10.1007/s11523-019-00685-x","title":"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Hormone","authors":[{"name":"Susan Feyerabend","is_ca":false},{"name":"Fred Saad","is_ca":true},{"name":"Nolen Joy Perualila","is_ca":false},{"name":"Suzy Van Sanden","is_ca":false},{"name":"Joris Diels","is_ca":false},{"name":"Tetsuro Ito","is_ca":false},{"name":"Peter De Porre","is_ca":false},{"name":"Karim Fizazi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06205601479162649,"gpt":0.388488184776486,"spread":0.3264321699848595,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05164541,0.001103449,0.001548843,0.000646997,0.0002329083,0.0009550205,0.001199638,0.0007274463,0.001876733],"category_scores_gemma":[0.08238903,0.0003837599,0.006062255,0.0009080028,0.0004644507,0.0006916473,0.001086582,0.00164076,0.0002324629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005831915,"about_ca_system_score_gemma":0.0007887302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003329161,"about_ca_topic_score_gemma":0.002192483,"domain_scores_codex":[0.9573145,0.03815401,0.0009601153,0.001505306,0.001728534,0.0003375167],"domain_scores_gemma":[0.8717231,0.1015376,0.01223281,0.01144763,0.002305624,0.0007531974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1912069,0.001053584,0.4780428,0.003194566,0.0819378,0.0002318156,0.0009755386,0.04988793,0.002341097,0.001289714,0.006547449,0.183291],"study_design_scores_gemma":[0.03837343,0.04498471,0.7236955,0.0004501979,0.07760158,0.0007716956,0.0005832264,0.09087846,0.00457248,0.003371536,0.0143372,0.0003799929],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618856,0.009788268,0.02093976,0.0005845695,0.0001884266,0.0005372297,0.003833433,0.0002837007,0.001959098],"genre_scores_gemma":[0.9892697,0.0006606723,0.005826938,0.0002615207,0.0001028189,0.000262367,0.003034496,0.000105448,0.0004760266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05164541,"threshold_uncertainty_score":0.2731303,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387032788","doi":"10.1007/s11523-023-01000-5","title":"A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Observational study; Gemcitabine; Cochrane Library; Internal medicine; MEDLINE; Chemotherapy; Cancer; Biliary tract cancer; Oncology; Intensive care medicine; Meta-analysis","authors":[{"name":"Vivian Peirce","is_ca":false},{"name":"Michael J. Paskow","is_ca":false},{"name":"Lei Qin","is_ca":false},{"name":"Ruby Dadzie","is_ca":false},{"name":"Maria Rapoport","is_ca":false},{"name":"Samantha J. Prince","is_ca":false},{"name":"Sukhvinder Johal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08894734557234671,"gpt":0.4349304150010871,"spread":0.3459830694287404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020707,0.001337843,0.006342493,0.05034558,0.00104436,0.004193733,0.001980829,0.002079975,0.004994831],"category_scores_gemma":[0.1046143,0.001188866,0.004867364,0.04831528,0.001289977,0.005039665,0.002664983,0.001135864,0.000651892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006628611,"about_ca_system_score_gemma":0.02383468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007272983,"about_ca_topic_score_gemma":0.02207477,"domain_scores_codex":[0.9664744,0.008105199,0.02027774,0.001502253,0.003129761,0.000510643],"domain_scores_gemma":[0.8738751,0.0871435,0.02394436,0.00256836,0.01171599,0.000752578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001211226,0.00001526421,0.001995736,0.9480059,0.002607532,0.0002148637,0.0006277231,0.0001155917,0.0002853211,0.0005213032,0.003627773,0.04186187],"study_design_scores_gemma":[0.00008656579,0.0001173886,0.006317731,0.9473237,0.01332316,0.0004326589,0.000701618,0.00007273869,0.0001628057,0.0003290207,0.03109978,0.0000328158],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004035723,0.9865876,0.0004887846,0.001617641,0.0003507496,0.001223159,0.004693605,0.00002769095,0.0009749754],"genre_scores_gemma":[0.02914301,0.9570967,0.004647537,0.002051858,0.0002271753,0.002970489,0.003497056,0.00002010347,0.0003461427],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.05034558,"threshold_uncertainty_score":0.1095104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406352769","doi":"10.1007/s11523-024-01126-0","title":"Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Paclitaxel; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Internal medicine; Oncology; Carcinoma; Head and neck cancer; Chemotherapy; Radiation therapy; Surgery","authors":[{"name":"Antoine Desîlets","is_ca":true},{"name":"Justin Lucas","is_ca":false},{"name":"Lisa Licitra","is_ca":false},{"name":"Sunny Lu","is_ca":false},{"name":"Archie Tse","is_ca":false},{"name":"Tom Tang","is_ca":false},{"name":"Kevin Dreyer","is_ca":false},{"name":"Nanhai He","is_ca":false},{"name":"L. Birgerson","is_ca":false},{"name":"Sandrine Faivre","is_ca":false},{"name":"Denis Soulières","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0106481787802106,"gpt":0.2746714922898457,"spread":0.264023313509635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001297134,0.0003455026,0.0006906859,0.0002289018,0.0001770435,0.0007079786,0.0002427401,0.0003919186,0.001099063],"category_scores_gemma":[0.001479873,0.0001436814,0.0006471934,0.0003761183,0.0002347228,0.0005859095,0.0002843536,0.001032786,0.000168463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006863059,"about_ca_system_score_gemma":0.0005299132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008199774,"about_ca_topic_score_gemma":0.002478983,"domain_scores_codex":[0.9995903,0.0001982924,0.00002247289,0.00004619059,0.00006765829,0.0000749297],"domain_scores_gemma":[0.9992452,0.0002542719,0.0002560415,0.00004763093,0.00007868306,0.0001182572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.242093,0.003981917,0.3862742,0.001703064,0.01095995,0.0002266739,0.0002521941,0.002000191,0.01712815,0.0005265387,0.005673261,0.3291808],"study_design_scores_gemma":[0.02698451,0.07190132,0.8697727,0.0003076215,0.01057986,0.0006393085,0.0004311595,0.002021129,0.005622554,0.0006371325,0.01102558,0.0000772897],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859329,0.01111041,0.00008000714,0.0007140139,0.00005482478,0.00006978613,0.0004109446,0.000009122662,0.001618032],"genre_scores_gemma":[0.9948936,0.002970628,0.0001377049,0.0005968296,0.00008043932,0.00004815185,0.0006739346,0.000003123889,0.0005956991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001297134,"threshold_uncertainty_score":0.006859958,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2900971116","doi":"10.1007/s11523-018-0603-0","title":"Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib","year":2018,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Carfilzomib; Medicine; Cytotoxicity; Refractory (planetary science); Cancer research; Proteasome inhibitor; Leukemia; Oncology; Immunology; Multiple myeloma; In vitro; Biochemistry","authors":[{"name":"Lucy Swift","is_ca":true},{"name":"Aarthi Jayanthan","is_ca":true},{"name":"Yibing Ruan","is_ca":true},{"name":"Ronald Anderson","is_ca":true},{"name":"Jessica Boklan","is_ca":false},{"name":"Tanya Trippett","is_ca":false},{"name":"Aru Narendran","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00839942384022,"gpt":0.2487751456260181,"spread":0.2403757217857981,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000184906,0.0002867414,0.0004468775,0.0002097657,0.0001726981,0.0002801925,0.0001716575,0.0001973609,0.0007842003],"category_scores_gemma":[0.0001444041,0.00009253313,0.0001532098,0.0002373932,0.0001630243,0.0001831862,0.00009007367,0.0003426571,0.000211906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003720502,"about_ca_system_score_gemma":0.0002622973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001207568,"about_ca_topic_score_gemma":0.001841192,"domain_scores_codex":[0.9998673,0.00002302457,0.000009741336,0.00001577214,0.00004505946,0.00003908231],"domain_scores_gemma":[0.99993,0.00001593594,0.000011715,0.00001132377,0.0000134836,0.00001754211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000374604,0.0001485179,0.0008848871,0.00005116776,0.00001679491,0.00009956517,0.00003826587,0.0004155996,0.9924951,0.0001379931,0.0001181036,0.005219445],"study_design_scores_gemma":[0.00007391901,0.002149448,0.009809409,0.000004662842,0.00004138153,0.0006087075,0.00003761835,0.001778958,0.9826273,0.00004434263,0.002819151,0.00000506307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959974,0.001493818,0.001269283,0.0000616211,0.000008351376,0.00005222463,0.0002730432,0.00003288854,0.0008113687],"genre_scores_gemma":[0.9975472,0.0007259811,0.000630406,0.00002237463,0.000007331076,0.00003257201,0.0004146649,0.000008499333,0.000610993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001207568,"threshold_uncertainty_score":0.002699435,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","authors":[{"name":"Fred Saad","is_ca":true},{"name":"Andrew J. Armstrong","is_ca":false},{"name":"Neal D. Shore","is_ca":false},{"name":"Daniel J. George","is_ca":false},{"name":"Mototsugu Oya","is_ca":false},{"name":"Mikio Sugimoto","is_ca":false},{"name":"Rana R. McKay","is_ca":false},{"name":"Maha Hussain","is_ca":false},{"name":"Noel W. Clarke","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04601313563003731,"gpt":0.3846335911876247,"spread":0.3386204555575874,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005075493,0.0002529385,0.000752428,0.0004056637,0.0001285014,0.0005356278,0.0002279146,0.0002803914,0.002290355],"category_scores_gemma":[0.000924819,0.000109356,0.0006754777,0.0003874316,0.0001851879,0.0003137851,0.0002037748,0.0008933724,0.0003976583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002787386,"about_ca_system_score_gemma":0.0005248522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002776016,"about_ca_topic_score_gemma":0.00143383,"domain_scores_codex":[0.9997125,0.0001228757,0.00002735361,0.00004492086,0.00006317192,0.00002902782],"domain_scores_gemma":[0.9995542,0.000135014,0.0001533877,0.00002582827,0.00002905375,0.0001024878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.09440894,0.001184007,0.01426101,0.002082904,0.002323415,0.0004276127,0.0001034714,0.003011372,0.0173673,0.001062753,0.009746375,0.8540209],"study_design_scores_gemma":[0.1304143,0.2086662,0.3055866,0.003545069,0.009413038,0.01893889,0.0006949899,0.02018346,0.03177047,0.02153867,0.2488096,0.0004386713],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.7730933,0.1980086,0.003721628,0.003878758,0.0005995904,0.0003620695,0.002079076,0.0003334745,0.01792348],"genre_scores_gemma":[0.9750178,0.01944574,0.001209598,0.0009034495,0.0002376268,0.00008251084,0.001062413,0.00001716543,0.002023728],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.002290355,"threshold_uncertainty_score":0.007662058,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2913025776","doi":"10.1007/s11523-018-00618-0","title":"Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Pharmacokinetics; Focal adhesion; Crossover; Crossover study; Pharmacology; Kinase; Pathology; Phosphorylation; Biochemistry","authors":[{"name":"Remy B. Verheijen","is_ca":false},{"name":"Diane A.J. van der Biessen","is_ca":false},{"name":"Sebastién J. Hotte","is_ca":true},{"name":"Lillian L. Siu","is_ca":true},{"name":"Anna Spreafico","is_ca":true},{"name":"Maja J.A. de Jonge","is_ca":false},{"name":"Linda Pronk","is_ca":false},{"name":"Filip De Vos","is_ca":false},{"name":"David Schnell","is_ca":false},{"name":"Hal W. Hirte","is_ca":true},{"name":"Neeltje Steeghs","is_ca":false},{"name":"Martijn P. Lolkema","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08393497142852478,"gpt":0.4287001567482334,"spread":0.3447651853197086,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005398017,0.001949314,0.004412544,0.0004950839,0.0005802758,0.001281319,0.0008824344,0.001981713,0.003893269],"category_scores_gemma":[0.006619819,0.001209915,0.001663415,0.0007169231,0.001906775,0.001798978,0.0005302199,0.003786777,0.0007189853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009588137,"about_ca_system_score_gemma":0.001300855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00068391,"about_ca_topic_score_gemma":0.001109346,"domain_scores_codex":[0.99644,0.002263869,0.0002743207,0.0004608924,0.0002744702,0.0002864383],"domain_scores_gemma":[0.9950601,0.001515562,0.001413862,0.0008000188,0.0004250513,0.0007853513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.966517,0.01857249,0.0006220777,0.0001472047,0.0007130557,0.00001869176,0.00006379471,0.0002913064,0.006028366,0.00007032009,0.0002805508,0.0066751],"study_design_scores_gemma":[0.5829831,0.4085729,0.00376237,0.00001204887,0.000639879,0.00002921426,0.00003611899,0.0009139203,0.001985561,0.00017089,0.0008625578,0.00003149919],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917169,0.00116101,0.001431399,0.000157159,0.0004241166,0.003680673,0.0006498737,0.00009663354,0.000682206],"genre_scores_gemma":[0.9848785,0.0009417903,0.003362718,0.0004720554,0.0005332698,0.006851703,0.000801503,0.00004710672,0.002111385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005398017,"threshold_uncertainty_score":0.02854782,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2516587078","doi":"10.1007/s11523-016-0448-3","title":"Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Temsirolimus; Clusterin; Medicine; Renal cell carcinoma; Pharmacology; Cancer research; Apoptosis; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Discovery and development of mTOR inhibitors","authors":[{"name":"Masatomo Nishikawa","is_ca":false},{"name":"Hideaki Miyake","is_ca":false},{"name":"Martin Gleave","is_ca":true},{"name":"Masato Fujisawa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02798368675883016,"gpt":0.3393615595728084,"spread":0.3113778728139782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002734199,0.0003281588,0.0004742334,0.000200669,0.0001795381,0.0002051755,0.0002576598,0.0003478493,0.0009025644],"category_scores_gemma":[0.0001032104,0.0001181321,0.0003367996,0.0002490268,0.0003570338,0.0002716134,0.0001280797,0.0009085654,0.0001607523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003350616,"about_ca_system_score_gemma":0.0005969421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001689677,"about_ca_topic_score_gemma":0.002215439,"domain_scores_codex":[0.9998568,0.00002916856,0.00001155664,0.00002705343,0.0000289457,0.00004642862],"domain_scores_gemma":[0.9999301,0.00001423346,0.00001308309,0.000008281962,0.0000088078,0.00002542026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002280192,0.00052491,0.0001776317,0.0000788308,0.00002367533,0.00004015807,0.00004571104,0.000436699,0.9930976,0.0001551358,0.0001640789,0.00297531],"study_design_scores_gemma":[0.0001747376,0.003346111,0.0019531,0.000002695305,0.00004739916,0.00006891724,0.00003293106,0.001876374,0.9913538,0.00002921353,0.001106716,0.000007907224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980689,0.0004725265,0.0004805904,0.00008687677,0.00003869285,0.00003101239,0.0001622276,0.00003823601,0.0006209158],"genre_scores_gemma":[0.9969139,0.0004359746,0.0009237107,0.00002542635,0.000008954717,0.00004282021,0.0003030106,0.000008767617,0.001337389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001689677,"threshold_uncertainty_score":0.003359675,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386346584","doi":"10.1007/s11523-023-00995-1","title":"Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Calgary","funders":"Jazz Pharmaceuticals Canada","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Internal medicine; Oncology; Chemotherapy; Surgery; Environmental health","authors":[{"name":"Devon J. Boyne","is_ca":true},{"name":"David E. Dawe","is_ca":true},{"name":"Huma Shakir","is_ca":true},{"name":"Ofodile Joe-Uzuegbu","is_ca":true},{"name":"Eliya Farah","is_ca":true},{"name":"Aliyah Pabani","is_ca":true},{"name":"Cristina Baratta","is_ca":false},{"name":"Darren R. Brenner","is_ca":true},{"name":"Winson Y. Cheung","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02779027094144856,"gpt":0.3760701408180536,"spread":0.3482798698766051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004924938,0.001223619,0.002612777,0.0008893671,0.0006272535,0.001617659,0.00161703,0.001415839,0.003020425],"category_scores_gemma":[0.006408768,0.0004908401,0.003293462,0.001658081,0.001642048,0.0008132317,0.0005258993,0.002463822,0.0002417361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01749978,"about_ca_system_score_gemma":0.01086345,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3474793,"about_ca_topic_score_gemma":0.4818041,"domain_scores_codex":[0.9957777,0.002541528,0.0001736894,0.0004087004,0.0006368085,0.0004614944],"domain_scores_gemma":[0.9962005,0.00118885,0.0009844032,0.0003213055,0.0004893264,0.0008156344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9424806,0.002654857,0.004203841,0.001210639,0.0057186,0.00006273012,0.0001285479,0.002548689,0.001628016,0.0007071877,0.001631211,0.03702509],"study_design_scores_gemma":[0.5939667,0.2342118,0.1222261,0.0006222131,0.02849615,0.0002334484,0.000416902,0.004822117,0.002101312,0.000642268,0.01198953,0.0002714719],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9563554,0.02953555,0.0005631376,0.001041421,0.0002969749,0.001104908,0.003706754,0.0000555051,0.007340396],"genre_scores_gemma":[0.992112,0.004118926,0.0005588676,0.0003299142,0.0001070048,0.0001543292,0.001312314,0.00001498379,0.001291657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6525208,"threshold_uncertainty_score":0.6909134,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","authors":[{"name":"Robert J. Motzer","is_ca":false},{"name":"Paul Russo","is_ca":false},{"name":"Viktor Grünwald","is_ca":false},{"name":"Yoshihiko Tomita","is_ca":false},{"name":"Bogdan Żurawski","is_ca":false},{"name":"Omi Parikh","is_ca":false},{"name":"Sebastiano Buti","is_ca":false},{"name":"Philippe Barthélémy","is_ca":false},{"name":"Jeffrey C. Goh","is_ca":false},{"name":"Dingwei Ye","is_ca":false},{"name":"Alejo Lingua","is_ca":false},{"name":"Jean‐Baptiste Lattouf","is_ca":true},{"name":"Laurence Albigès","is_ca":false},{"name":"Saby George","is_ca":false},{"name":"Brian Shuch","is_ca":false},{"name":"Jeffrey A. Sosman","is_ca":false},{"name":"Michael Staehler","is_ca":false},{"name":"Sergio Vázquez Estévez","is_ca":false},{"name":"Burçin Şimşek","is_ca":false},{"name":"Julia Spiridigliozzi","is_ca":false},{"name":"Aleksander Chudnovsky","is_ca":false},{"name":"Axel Bex","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1294819005494149,"gpt":0.4061370170159111,"spread":0.2766551164664962,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003516877,0.001500574,0.0027321,0.0004966203,0.0004544389,0.001826034,0.0009719961,0.002822652,0.01914242],"category_scores_gemma":[0.004270334,0.0006795808,0.003729358,0.0004843982,0.0005838756,0.0008638684,0.0002916179,0.002682645,0.002968339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006777559,"about_ca_system_score_gemma":0.001489647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007633024,"about_ca_topic_score_gemma":0.00180104,"domain_scores_codex":[0.9988682,0.0006351139,0.0001374578,0.0001494938,0.0001209794,0.00008879966],"domain_scores_gemma":[0.9980983,0.0008070579,0.0004794537,0.00009161072,0.0002125902,0.0003108552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8709019,0.004384201,0.0006938725,0.0226891,0.01091147,0.00009937903,0.0000808628,0.0005180157,0.00434561,0.0005940654,0.01495936,0.0698223],"study_design_scores_gemma":[0.9611006,0.02637937,0.001285437,0.0009804603,0.004395025,0.00004209,0.00002115631,0.0001926937,0.0004183818,0.0003199506,0.004840447,0.00002438702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4446293,0.3856553,0.006356975,0.02325095,0.01444381,0.05520126,0.029483,0.001176096,0.03980332],"genre_scores_gemma":[0.7966594,0.1074269,0.007601855,0.02034483,0.008347743,0.02551733,0.01070208,0.0001661373,0.02323378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01914242,"threshold_uncertainty_score":0.0640378,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021963511","doi":"10.1007/s11523-008-0093-6","title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies","year":2008,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Parks and Wilderness Society","funders":"","keywords":"Medicine; Cetuximab; Epidermal growth factor receptor; EGFR inhibitors; Tyrosine kinase; Lung cancer; Cancer; Colorectal cancer; Cancer research; Drug resistance; Gefitinib; Erlotinib; Signal transduction; Targeted therapy; Receptor tyrosine kinase; Bioinformatics; Oncology; Internal medicine; Receptor; Biology","authors":[{"name":"Alexandra Eyzaguirre","is_ca":false},{"name":"Elizabeth Buck","is_ca":false},{"name":"Kenneth K. Iwata","is_ca":false},{"name":"John D. Haley","is_ca":false},{"name":"Mark Miglarese","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01352074422015656,"gpt":0.3217577086328896,"spread":0.3082369644127331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004493175,0.000585912,0.001852943,0.001131823,0.0002295654,0.002152071,0.001040447,0.00130112,0.001556166],"category_scores_gemma":[0.005510672,0.0002832977,0.0005128292,0.000783982,0.000741936,0.001622301,0.0004536672,0.001524033,0.0004561443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001226475,"about_ca_system_score_gemma":0.0007607391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002059071,"about_ca_topic_score_gemma":0.0002794562,"domain_scores_codex":[0.998693,0.0006611245,0.0001085601,0.0001498211,0.0003068932,0.00008054939],"domain_scores_gemma":[0.9979735,0.001270309,0.0003920296,0.00008577458,0.0001738829,0.0001044462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00199438,0.0008295524,0.0741641,0.00106583,0.0003547462,0.001736312,0.0003403262,0.01070624,0.02663806,0.02533824,0.009369139,0.8474631],"study_design_scores_gemma":[0.002287629,0.01866261,0.276176,0.00219717,0.002804598,0.04944619,0.002400834,0.08969069,0.1095217,0.1573348,0.2888554,0.0006224121],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3183106,0.5243379,0.06249348,0.05819128,0.0006142809,0.0006629063,0.0006278126,0.000824706,0.03393704],"genre_scores_gemma":[0.8421857,0.1317775,0.01702393,0.005136912,0.0009727803,0.000320014,0.0003121474,0.00006851584,0.002202693],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004493175,"threshold_uncertainty_score":0.02376246,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3111069302","doi":"10.1007/s11523-020-00778-y","title":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Population; Cohort; Retrospective cohort study; Oncology; Cancer; Immunotherapy; Environmental health","authors":[{"name":"François Laliberté","is_ca":false},{"name":"Monika Raut","is_ca":false},{"name":"Xiaoqin Yang","is_ca":false},{"name":"Guillaume Germain","is_ca":true},{"name":"Akash Nahar","is_ca":false},{"name":"Kaushal Desai","is_ca":false},{"name":"Sean D. MacKnight","is_ca":false},{"name":"Shuvayu S. Sen","is_ca":false},{"name":"Mei Sheng Duh","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03138123723126232,"gpt":0.292119504055217,"spread":0.2607382668239546,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008762259,0.0001944088,0.0003541076,0.00116693,0.0002977991,0.0008164354,0.0004496539,0.0004633782,0.0008139148],"category_scores_gemma":[0.003191153,0.0002271956,0.0006319414,0.002585478,0.0002317942,0.0005987692,0.0006582302,0.0005963038,0.0001340874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001167654,"about_ca_system_score_gemma":0.0007284501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02527893,"about_ca_topic_score_gemma":0.0320619,"domain_scores_codex":[0.998674,0.0004435595,0.0002401962,0.0002468189,0.0002285381,0.0001668208],"domain_scores_gemma":[0.9961686,0.0004573001,0.002651097,0.00008829756,0.0002469069,0.0003878122],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00006189173,0.00002495837,0.9990589,0.000009512754,0.00006801699,0.00003458682,0.00004187493,0.00004809825,0.00002461886,0.0000133446,0.0001643899,0.0004498342],"study_design_scores_gemma":[0.000007090417,0.0000461599,0.9987204,0.00001343372,0.00003164585,0.0001532951,0.0003294983,0.0004042175,0.00002578643,0.00001497514,0.0002483465,0.000005117654],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972996,0.0002772087,0.00003711601,0.0001152656,0.000005041462,0.00001011342,0.002025235,0.000002204141,0.0002283168],"genre_scores_gemma":[0.9982625,0.0001677348,0.00006350965,0.00006779252,0.00001062283,0.00001674847,0.001373991,0.000001121402,0.0000361014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02527893,"threshold_uncertainty_score":0.05026358,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392654691","doi":"10.1007/s11523-024-01034-3","title":"Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","year":2024,"lang":"en","type":"letter","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; Placebo; Epidermal growth factor receptor; Stage (stratigraphy); Cancer; Pathology; Erlotinib; Biology","authors":[{"name":"Masahiro Tsuboi","is_ca":false},{"name":"Roy S. Herbst","is_ca":false},{"name":"Thomas John","is_ca":false},{"name":"Terufumi Kato","is_ca":false},{"name":"Margarita Majem","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Jie Wang","is_ca":false},{"name":"Jonathan W. Goldman","is_ca":false},{"name":"Shun Lü","is_ca":false},{"name":"Filippo de Marinis","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Ki Hyeong Lee","is_ca":false},{"name":"Nhieu Thi Le","is_ca":false},{"name":"Arunee Dechaphunkul","is_ca":false},{"name":"Dariusz M. Kowalski","is_ca":false},{"name":"Laura Bonanno","is_ca":false},{"name":"Manuel Dómine","is_ca":false},{"name":"Lynne Poole","is_ca":false},{"name":"Ana Bolanos","is_ca":true},{"name":"Yuri Rukazenkov","is_ca":false},{"name":"Yi‐Long Wu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05860293502871478,"gpt":0.4132749408906006,"spread":0.3546720058618859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002686217,0.0006790645,0.001081355,0.0006873924,0.001142439,0.00218113,0.001070192,0.009439343,0.005339583],"category_scores_gemma":[0.006675435,0.000264224,0.001050955,0.0007455698,0.00069102,0.001370487,0.0003161372,0.005726732,0.006628429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004143484,"about_ca_system_score_gemma":0.002082372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002067549,"about_ca_topic_score_gemma":0.003564487,"domain_scores_codex":[0.9984581,0.000411435,0.0003328368,0.0002050871,0.000385645,0.0002069076],"domain_scores_gemma":[0.9954673,0.001861413,0.0003888267,0.0001244633,0.001533512,0.0006243695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007057412,0.0002038973,0.002127283,0.0004568787,0.00005810185,0.001553969,0.00005668171,0.0001696683,0.0008658839,0.001513081,0.8987345,0.09355427],"study_design_scores_gemma":[0.0009409843,0.00161533,0.008770278,0.001266894,0.0002846323,0.004552567,0.0001928769,0.0008850071,0.001591728,0.004088539,0.9757392,0.00007197297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.004573244,0.02996458,0.0004497937,0.8789054,0.06005795,0.0001444956,0.00105488,0.0001431434,0.02470656],"genre_scores_gemma":[0.02534493,0.02610119,0.0008187925,0.6349901,0.2829768,0.0001932799,0.001034854,0.00008135474,0.02845866],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.009439343,"threshold_uncertainty_score":0.03006327,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4411055081","doi":"10.1007/s11523-025-01153-5","title":"Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Newfoundland and Labrador; AstraZeneca","keywords":"Medicine; Osimertinib; Concordance; Acquired resistance; Biopsy; Oncology; Circulating tumor DNA; Pathology; Internal medicine; Cancer; Adenocarcinoma","authors":[{"name":"Fenneke Zwierenga","is_ca":false},{"name":"M Benthe Muntinghe-Wagenaar","is_ca":false},{"name":"Pim Rozendal","is_ca":false},{"name":"Adrianus J. de Langen","is_ca":false},{"name":"Lizza Hendriks","is_ca":false},{"name":"Michel M. van den Heuvel","is_ca":false},{"name":"Cor van der Leest","is_ca":false},{"name":"Sayed M.S. Hashemi","is_ca":false},{"name":"Paul van der Leest","is_ca":false},{"name":"T. Jeroen N. Hiltermann","is_ca":false},{"name":"Ed Schuuring","is_ca":false},{"name":"Anthonie J. van der Wekken","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006775695507202522,"gpt":0.2802244547159031,"spread":0.2734487592087006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003661901,0.000154992,0.0002009616,0.0003808674,0.0001310843,0.0002807677,0.0001574574,0.0002805839,0.0009661994],"category_scores_gemma":[0.001245925,0.0001273866,0.00008736201,0.000244346,0.000155112,0.0001816968,0.000146737,0.0002178722,0.0001638544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001732819,"about_ca_system_score_gemma":0.00009301315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003712238,"about_ca_topic_score_gemma":0.000577579,"domain_scores_codex":[0.9997721,0.00004865979,0.00003412138,0.00005926832,0.00006234352,0.00002356097],"domain_scores_gemma":[0.9992048,0.0002128476,0.000335498,0.00003624924,0.0001075271,0.0001029805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007830525,0.00005488242,0.9755369,0.00002467724,0.00003235063,0.0005430071,0.0000871141,0.0001333243,0.01673812,0.00001276208,0.00004817022,0.00600567],"study_design_scores_gemma":[0.00003870397,0.001169891,0.9840349,0.000008094429,0.00005022527,0.005811771,0.0001147415,0.0007786409,0.007589574,0.00002689816,0.0003713014,0.000005296381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.999481,0.0001836504,0.0001126909,0.000006977703,0.0000017845,0.000004466927,0.00003984876,0.000003722808,0.000165907],"genre_scores_gemma":[0.9996954,0.00004398124,0.0001009474,0.000007776815,0.000002675035,0.000003913681,0.00007381885,7.768137e-7,0.00007080942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009661994,"threshold_uncertainty_score":0.003232241,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404024879","doi":"10.1007/s11523-024-01111-7","title":"Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Victoria","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Chemoradiotherapy; Stage (stratigraphy); Oncology; Systemic therapy; Lung cancer; Internal medicine; Cancer; Pathology; Immunotherapy","authors":[{"name":"Doran Ksienski","is_ca":true},{"name":"Pauline T. Truong","is_ca":true},{"name":"Jeffrey N. Bone","is_ca":true},{"name":"Sarah Egli","is_ca":false},{"name":"Melissa Clarkson","is_ca":false},{"name":"Tiffany Patterson","is_ca":false},{"name":"Mary Lesperance","is_ca":true},{"name":"Suganija Lakkunarajah","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02161984062590372,"gpt":0.3270869353708606,"spread":0.3054670947449569,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003629977,0.0001347912,0.0005202836,0.0001518587,0.0001857602,0.0003507085,0.0001830858,0.0002733693,0.0008575329],"category_scores_gemma":[0.001025878,0.00005985087,0.0003720712,0.0002116178,0.0001562768,0.0003464019,0.0002082948,0.0005111312,0.0001714383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003619367,"about_ca_system_score_gemma":0.0002755015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001200087,"about_ca_topic_score_gemma":0.003009213,"domain_scores_codex":[0.9997726,0.00003873362,0.00001600965,0.00004181714,0.00004374661,0.00008718249],"domain_scores_gemma":[0.9995219,0.0001363496,0.0001371015,0.00002535365,0.00003352796,0.0001458373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02854617,0.0006228522,0.8873761,0.00005453104,0.0004903611,0.0008527584,0.0001532482,0.0004706819,0.006277915,0.0001561441,0.0006023993,0.07439674],"study_design_scores_gemma":[0.0001103747,0.003403898,0.9939282,0.000009025198,0.0001422246,0.0006049491,0.0000856741,0.0003969243,0.0005022341,0.0001129826,0.0006964014,0.000007067014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983125,0.0009179114,0.00005395732,0.00005791503,0.00001477597,0.000004427143,0.00007769505,0.000001670626,0.0005592069],"genre_scores_gemma":[0.9992667,0.000204673,0.00002539145,0.00004497729,0.00001456341,0.000002390662,0.0001499027,0.000001090659,0.0002902793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001200087,"threshold_uncertainty_score":0.002868712,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4416937861","doi":"10.1007/s11523-025-01187-9","title":"Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Standard of care; MEDLINE; Patient care; Neoplasm staging; Overall survival","authors":[{"name":"Erick Figueiredo Saldanha","is_ca":true},{"name":"Mariana Macambira Noronha","is_ca":false},{"name":"Pedro Cotta Abrahão Reis","is_ca":false},{"name":"Pedro Robson Costa Passos","is_ca":false},{"name":"Valbert Oliveira Costa Filho","is_ca":false},{"name":"Anelise Poluboiarinov Cappellaro","is_ca":false},{"name":"Luiz F. Costa de Almeida","is_ca":false},{"name":"Jean Henri Maselli-Shoueri","is_ca":true},{"name":"Carlos Diego Holanda Lopes","is_ca":true},{"name":"Luís Felipe Leite","is_ca":false},{"name":"Maurício Fernando Silva Almeida Ribeiro","is_ca":false},{"name":"Daniel Vilarim Araújo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04936342569924775,"gpt":0.3741072122374792,"spread":0.3247437865382315,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005584232,0.002548313,0.007475336,0.001535615,0.0006077714,0.002345303,0.001532525,0.002008014,0.004156571],"category_scores_gemma":[0.009608245,0.001535287,0.03761953,0.002579018,0.0006748649,0.001587081,0.001393756,0.002582947,0.0005059803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001188114,"about_ca_system_score_gemma":0.0009592149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00631786,"about_ca_topic_score_gemma":0.01477141,"domain_scores_codex":[0.9957249,0.001800652,0.0006326113,0.001167515,0.0003255028,0.0003487433],"domain_scores_gemma":[0.9948838,0.002827686,0.001077489,0.0006248012,0.000352204,0.0002339401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.01394038,0.00004297959,0.03369724,0.01172666,0.9323681,0.0001589069,0.0000543228,0.0007503288,0.0007403866,0.0001021522,0.0006102184,0.005808383],"study_design_scores_gemma":[0.001688869,0.0004949619,0.01820013,0.000585908,0.9772457,0.0001107795,0.00004144806,0.0003649387,0.0001382054,0.000220223,0.0008795495,0.00002935051],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2137742,0.7761487,0.003678574,0.0007365684,0.0009765477,0.0001628937,0.002920088,0.000184264,0.001418017],"genre_scores_gemma":[0.9451728,0.05011958,0.001128644,0.001097808,0.0003774066,0.0001251195,0.001049903,0.00008352175,0.0008451111],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.007475336,"threshold_uncertainty_score":0.02953255,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417274131","doi":"10.1007/s11523-025-01186-w","title":"Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada); Alberta Children's Hospital","funders":"Genentech; Roche","keywords":"Young adult; Chemotherapy; Venetoclax; Phases of clinical research; Solid tumor","authors":[{"name":"Alba Rubio‐San‐Simón","is_ca":false},{"name":"Lynley V. Marshall","is_ca":false},{"name":"François Doz","is_ca":false},{"name":"Jaume Catalá‐Mora","is_ca":false},{"name":"Kevin Bielamowicz","is_ca":false},{"name":"Nadège Corradini","is_ca":false},{"name":"Anne‐Marie Langevin","is_ca":false},{"name":"Aru Narendran","is_ca":true},{"name":"Amy Smith","is_ca":false},{"name":"C. Michel Zwaan","is_ca":false},{"name":"Deborah Gho","is_ca":false},{"name":"Alison K. Cardenas","is_ca":false},{"name":"Stephen C. Fowler","is_ca":false},{"name":"Cecile Guizani","is_ca":false},{"name":"Vanessa Breton","is_ca":true},{"name":"Beate Wulff","is_ca":false},{"name":"Ronald J. Bernardi","is_ca":false},{"name":"Tanya Trippett","is_ca":false},{"name":"Quentin Campbell-Hewson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01157666888915094,"gpt":0.3287658524750596,"spread":0.3171891835859086,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001038519,0.0007214528,0.001643215,0.0003714543,0.0001905106,0.0007572059,0.0005080671,0.000520931,0.001262659],"category_scores_gemma":[0.000693658,0.0003069929,0.0007842944,0.0005031814,0.0005442775,0.0005890996,0.0002324015,0.001781777,0.0002820588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004859153,"about_ca_system_score_gemma":0.0008793829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006926017,"about_ca_topic_score_gemma":0.002058457,"domain_scores_codex":[0.999647,0.0002076847,0.00001824564,0.00004521318,0.00002626158,0.00005566856],"domain_scores_gemma":[0.9994931,0.0001291229,0.0001031526,0.00004247905,0.00001669938,0.0002154226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6743121,0.05139829,0.0367628,0.0007857456,0.003287994,0.0002946687,0.0004556466,0.002730174,0.02944272,0.000369372,0.002712255,0.1974482],"study_design_scores_gemma":[0.3330171,0.5888988,0.06253518,0.0001103427,0.002380088,0.0005314403,0.0002470498,0.001777846,0.005573314,0.0002587932,0.00462816,0.00004200017],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967719,0.001924669,0.0001289065,0.0001368909,0.00003660147,0.0001834612,0.0002780806,0.00002214172,0.0005173195],"genre_scores_gemma":[0.9928838,0.003589904,0.0007964466,0.0003537122,0.0001269813,0.0003678783,0.0009947051,0.00001643717,0.0008700814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001643215,"threshold_uncertainty_score":0.00549227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4238104384","doi":"10.1007/s11523-020-00772-4","title":"Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Medicine; Paragraph; Rituximab; Follicular lymphoma; Lymphoma; Internal medicine; Medical physics; Oncology; World Wide Web","authors":[{"name":"Dietger Niederwieser","is_ca":false},{"name":"Caroline Hamm","is_ca":true},{"name":"Patrick Cobb","is_ca":false},{"name":"Mindy Mo","is_ca":false},{"name":"Cecily Forsyth","is_ca":false},{"name":"Alessandra Tucci","is_ca":false},{"name":"Vladimir Hanes","is_ca":false},{"name":"Vincent Delwail","is_ca":false},{"name":"Roman Hájek","is_ca":false},{"name":"David Chien","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02245929450660679,"gpt":0.2756866625027647,"spread":0.2532273679961579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006895735,0.002446721,0.003003762,0.003052399,0.002152738,0.004834455,0.004230013,0.01176122,0.04952354],"category_scores_gemma":[0.105651,0.0016929,0.00330531,0.002419861,0.002286391,0.001764765,0.00134016,0.01886864,0.02795099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005178288,"about_ca_system_score_gemma":0.006480531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01781473,"about_ca_topic_score_gemma":0.01671161,"domain_scores_codex":[0.9920816,0.0015415,0.001742047,0.0008921791,0.002997125,0.000745483],"domain_scores_gemma":[0.9447288,0.0213693,0.00315594,0.002438874,0.02608217,0.002224805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008222894,0.000005594079,0.00003638386,0.0001660319,0.00001974324,0.00007470974,0.00001080511,0.00002178578,0.00002856319,0.000145967,0.9974795,0.001928678],"study_design_scores_gemma":[0.0006536356,0.0001013617,0.001929102,0.001252608,0.0002256286,0.0005542048,0.0000714983,0.0004220189,0.0005092212,0.001631236,0.9925745,0.00007490629],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001310794,0.001344381,0.0003111891,0.08255854,0.9122275,0.00004102745,0.001476981,0.0002784017,0.00163081],"genre_scores_gemma":[0.0099301,0.006792943,0.003043107,0.2723977,0.59893,0.0004423868,0.002941555,0.001296739,0.1042255],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.04952354,"threshold_uncertainty_score":0.1656727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","authors":[{"name":"G. Robinet","is_ca":false},{"name":"Fabrice Barlési","is_ca":false},{"name":"P. Fournel","is_ca":false},{"name":"H. Bérard","is_ca":true},{"name":"R. Corre","is_ca":false},{"name":"A. Vergnenègre","is_ca":false},{"name":"L. Falchero","is_ca":false},{"name":"P.J. Souquet","is_ca":false},{"name":"A. Tisseron-Carrasco","is_ca":false},{"name":"C. Chouaïd","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0137413535267044,"gpt":0.3733654310320024,"spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002423721,0.002935534,0.006966312,0.0008864314,0.0008151674,0.001963875,0.001488974,0.002415013,0.006063129],"category_scores_gemma":[0.001224399,0.001239746,0.003711309,0.0008674159,0.00192763,0.0022988,0.000607156,0.00555552,0.00131632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002301407,"about_ca_system_score_gemma":0.002239838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002928834,"about_ca_topic_score_gemma":0.007293588,"domain_scores_codex":[0.9988457,0.0004427224,0.00005096605,0.0002810384,0.00008193243,0.0002976419],"domain_scores_gemma":[0.9988582,0.0001991432,0.0002101876,0.0001079031,0.00006001913,0.0005645496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9510413,0.01729371,0.001405247,0.0005143055,0.002008368,0.00005956375,0.00007610891,0.001092986,0.003448543,0.0001258742,0.001467228,0.02146664],"study_design_scores_gemma":[0.8570209,0.1375127,0.00247833,0.00002522769,0.0008918879,0.00006578738,0.00002627135,0.000424974,0.0005830186,0.00008510052,0.0008602093,0.00002559981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873152,0.004733432,0.000729646,0.0006918164,0.0005958992,0.00270022,0.001387618,0.0001488413,0.001697357],"genre_scores_gemma":[0.9849583,0.003687061,0.001490385,0.00113533,0.0005520124,0.003046815,0.001998436,0.00007139807,0.00306032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006966312,"threshold_uncertainty_score":0.02028322,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}